KY02111: promotes cardiac differentiation of pluripotent stem cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 468595 |
| CHEMBL ID | 1397 |
| CHEBI ID | 64355 |
| SCHEMBL ID | 991747 |
| MeSH ID | M0265888 |
| PubMed CID | 8582409 |
| CHEMBL ID | 3186128 |
| SCHEMBL ID | 15063115 |
| MeSH ID | M0265888 |
| Synonym |
|---|
| AC-1350 |
| c37h42f2n8o4 |
| AB01274762-01 |
| noxafil |
| posaconazole sp |
| noxafil (tn) |
| D02555 |
| posaconazole (jan/usan/inn) |
| 4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1s,2s)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one |
| posaconazole , |
| 1-((1s,2s)-1-ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5s,3r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one |
| POS , |
| 171228-49-2 |
| sch-56592 |
| sch 56592 |
| sch56592 |
| DB01263 |
| d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1s,2s)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1h-1,2,4-triazol-1-yl)- |
| 4-(p-(4-(p-(((3r,5r)-5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1s,2s)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one |
| posaconazole [usan:inn:ban] |
| 3h-1,2,4-triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3r-(3alpha(1s*,2s*),5alpha))- |
| posaconazole in combination with mgcd290 |
| AKOS005145917 |
| CHEMBL1397 , |
| chebi:64355 , |
| (-)-posaconazole |
| 4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2s,3s)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one |
| 4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2h-1,2,4-triazol-3(4h)-one |
| 4-(4-(4-(4-(((5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2h-1,2,4-triazol-3(4h)-one |
| bdbm50181473 |
| pasaconazole |
| 4-[4-(4-{4-[(r)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1s,2s)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one |
| NCGC00185736-01 |
| 6tk1g07bhz , |
| unii-6tk1g07bhz |
| hsdb 7421 |
| dtxcid401474254 |
| tox21_113620 |
| dtxsid6049066 , |
| cas-171228-49-2 |
| HY-17373 |
| CS-0998 |
| 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2s,3s)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol |
| schering 56592 |
| 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol |
| posaconazole [green book] |
| 3h-1,2,4-triazol-3-one, 4-[4-[4-[4-[[5-(2,4-difluorophenyl)tetrahydro-5-(1h-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, [3r-[3alpha(1s*,2s*),5alpha]]- |
| posaconazole [who-dd] |
| posaconazole [jan] |
| posaconazole [mi] |
| posaconazole [hsdb] |
| posaconazole [inn] |
| d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)- |
| posaconazole [mart.] |
| posaconazole [orange book] |
| posaconazole [usan] |
| posaconazole [vandf] |
| posaconazole [ema epar] |
| S1257 |
| NCGC00274060-01 |
| tox21_113620_1 |
| P-7020 |
| posaconazole, antibiotic for culture media use only |
| RAGOYPUPXAKGKH-XAKZXMRKSA-N |
| 4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2s,3s)-2-hydroxypentan-3-yl)-1h-1,2,4-triazol-5(4h)-one |
| SCHEMBL991747 |
| KS-1413 |
| posaconazol |
| AB01274762_02 |
| posaconazole, vetranal(tm), analytical standard |
| mfcd00941162 |
| mmv688774 |
| SW219391-1 |
| 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol |
| 177571-33-4 |
| P2477 |
| BCP01102 |
| Q906453 |
| AMY30591 |
| CCG-270387 |
| d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-; noxafil; posaconazole; sch 565 |
| NCGC00274060-07 |
| d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)- 4-((4-(4-(4-(1-((1s,2s)-1-ety |
| gtpl11428 |
| NCGC00274060-02 |
| BP164281 |
| BP163593 |
| posaconazole - form i |
| posaconazole- bio-x |
| BP163592 |
| posaconazole - form iii |
| 4-{4-[4-(4-{[(3r,5r)-5-(2,4-difluorophenyl)-5-[(1h-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2s,3s)-2-hydroxypentan-3-yl]-4,5-dihydro-1h-1,2,4-triazol-5-one |
| EN300-19769273 |
| d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-( 1h-1,2,4-triazol-1-yl)-? |
| posaconazolum |
| noxafil powdermix kit |
| 4-(4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one |
| posaconazole delayed-release |
| (3r-cis)-4- |
| 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4- |
| posaconazole (mart.) |
| j02ac04 |
| 4-(4-(4-(4-(((3r,5r)-5-(2,4-difluorophenyl)-5-((1h-1,2,4-triazol-1-yl)methyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2s,3s)-2-hydroxypentan-3-yl)-2,4-dihydro-3h-1,2,4-triazol-3-one |
| AKOS007976129 |
| n-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide |
| NCGC00347949-01 |
| ky 02111 |
| 1118807-13-8 |
| n-(6-chlorobenzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide |
| ky02111 |
| CS-1975 |
| HY-13815 |
| AM81229 |
| benzenepropanamide, n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxy- |
| n-(6-chloro-benzothiazol-2-yl)-3-(3,4-dimethoxy-phenyl)-propionamide |
| n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide |
| c18h17cln2o3s |
| SCHEMBL15063115 |
| DTXSID80429194 |
| HB3465 |
| n-(6-chloro-2-benzothiazolyl)-3,4-d imethoxybenzenepropanamide |
| AC-32857 |
| CHEMBL3186128 |
| J-002654 |
| ky-02111 |
| HMS3653K03 |
| mfcd08483062 |
| ky0211 |
| NCGC00347949-11 |
| SW219524-1 |
| FT-0713062 |
| BCP07010 |
| Z27365775 |
| S7096 |
| EX-A2089 |
| AS-16445 |
| unii-6axh36yf6m |
| CCG-268372 |
| 2-(3-(3,4-dimethoxyphenyl)propanamido)-6-chlorobenzothiazole |
| 6AXH36YF6M , |
| NCGC00347949-08 |
| BK162779 |
| EN300-1266069 |
| n-(6-chloro-2-benzothiazolyl)-3,4-dimethoxy-benzenepropanamide |
Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. It is used as a prophylaxis for invasive fungal infections in allogeneic stem cell transplant (SCT) recipients.
Posaconazole has a broad spectrum of activity, a favorable safety profile and excellent prophylactic activity in adults. To date, serious side effects are rare, even with prolonged use.
Posaconazole has shown promising clinical efficacy against life-threatening fungal infections. It has been recently approved by the US FDA for the treatment of oropharyngeal candidiasis, and the prophylaxis of invasive Aspergillus and Candida infections.
Posaconazole was found to inhibit amoeba growth within the first 12 hours of exposure, which was faster than any currently used drug. It may also allow a reduction in the dose of liposomal amphotericin B.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Posaconazole was found to inhibit amoeba growth within the first 12 hours of exposure, which was faster than any currently used drug." | ( Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis. Colon, BL; Guy, RK; Kyle, DE; Rice, CA, 2019) | 1.54 |
| "Posaconazole may also allow a reduction in the dose of liposomal amphotericin B, resulting in better tolerance." | ( Use of posaconazole in the treatment of infective rhinocerebral mucormycosis. Butler, C; Clarke, P; Habibi, M; Howard, D; Kulendra, K, 2010) | 1.54 |
Posaconazole salvage treatment was effective antifungal therapy for IFI. All posaconazol-treated animals had negative haemocultures at 54 days post infection. 50% of those treated with benznidazole had positive results.
Long-term therapy did not increase the risk of any individual adverse event. No unique adverse event was observed with longer exposure to posaconazole.
Posaconazole is an important antifungal agent for both prophylaxis and treatment of IFIs. However, detailed pharmacokinetic data are limited among LTRs, particularly those with cystic fibrosis (CF)
Miltefosine demonstrated synergy in 8/20 (40%) and 4/20(20%) instances when combined with posaconazole and voriconazole, respectively. To our knowledge, there have been no published cases of clinically significant posaconzole-digoxin drug-drug interactions.
Posaconazole has an important role in the prophylaxis and salvage treatment of invasive fungal infections. Poor and variable bioavailability remains an important clinical concern.
Limited data exist on intravenous (IV) posaconazole dosing and the risk for hepatotoxicity it confers to children. The aim of this work was, therefore, to describe the total and unbound population pharmacokinetics of intravenous posaconzole in criticall.
| Role | Description |
|---|---|
| trypanocidal drug | A drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
| N-arylpiperazine | |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| oxolanes | Any oxacycle having an oxolane (tetrahydrofuran) skeleton. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| conazole antifungal drug | Any conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans. |
| triazole antifungal drug | Any triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.4505 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 26.8325 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 22.3872 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 26.8325 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.7499 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2492 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 14.1402 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743042; AID743054 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 5.9557 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 9.8374 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 29.8493 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.2078 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 9.5205 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.7255 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 5.6710 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 7.7336 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 29.8470 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 10.5909 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 16.2285 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| G | Vesicular stomatitis virus | Potency | 10.8797 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| polyprotein | Zika virus | Potency | 22.3872 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 33.4889 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 33.4889 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 28.3816 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259395 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 25.1567 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 10.5901 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 8.4127 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Interferon beta | Homo sapiens (human) | Potency | 10.8797 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 10.8797 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 8.4127 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 12.4562 | 0.0096 | 10.5250 | 35.4813 | AID1479145; AID1479148 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 10.8797 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 5.3080 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 5.3080 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 10.8797 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 3.0112 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 14.1286 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253; AID1259255; AID1259256 |
| G | Vesicular stomatitis virus | Potency | 6.0081 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Interferon beta | Homo sapiens (human) | Potency | 6.0081 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 6.0081 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 6.0081 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 6.0081 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 8.1000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | IC50 (µMol) | 0.9210 | 0.0020 | 0.9818 | 4.7300 | AID1487223; AID1487224 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 0.2458 | 0.0001 | 1.7536 | 10.0000 | AID1180169; AID1487215; AID1557089; AID394828; AID480595 |
| Aromatase | Homo sapiens (human) | IC50 (µMol) | 8.4000 | 0.0000 | 1.2904 | 10.0000 | AID1487225 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 58.1000 | 0.0000 | 2.8005 | 10.0000 | AID1487219; AID1487220 |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 0.3100 | 0.0005 | 0.2902 | 2.7800 | AID1487221 |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | IC50 (µMol) | 0.0210 | 0.0001 | 0.2738 | 3.5000 | AID1487222 |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | IC50 (µMol) | 0.4640 | 0.0010 | 1.7070 | 10.0000 | AID1383443; AID1882559 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 (µMol) | 6.0000 | 0.0040 | 1.9666 | 10.0000 | AID1873196 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sterol 14-alpha-demethylase | Aspergillus flavus AF70 | Kd | 0.1310 | 0.0560 | 0.0935 | 0.1310 | AID1498549 |
| 14-alpha sterol demethylase | Aspergillus niger | Kd | 0.1310 | 0.0560 | 0.0935 | 0.1310 | AID1498549 |
| Lanosterol 14-alpha demethylase | Candida albicans SC5314 | Kd | 0.0810 | 0.0450 | 0.0970 | 0.1650 | AID1498548 |
| Sterol 14-alpha demethylase | Aspergillus fumigatus Af293 | Kd | 2.6900 | 1.0100 | 3.0300 | 4.7900 | AID575747 |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | Kd | 0.0390 | 0.0180 | 0.4285 | 2.3000 | AID1546308; AID728147 |
| 14-alpha sterol demethylase | Aspergillus fumigatus | Kd | 0.0730 | 0.0310 | 0.8482 | 4.0300 | AID575755 |
| 14-alpha sterol demethylase | Aspergillus fumigatus | Kd | 0.1310 | 0.0560 | 0.0935 | 0.1310 | AID1498549 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID563830 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID582241 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID582250 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID575361 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522448 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564622 | Antimicrobial activity against Aspergillus fumigatus isolate 45 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564615 | Antimicrobial activity against Aspergillus fumigatus isolate 38 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID598304 | Antimicrobial activity against Candida albicans ATCC 90028 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID522518 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564403 | Antimicrobial activity against Aspergillus fumigatus isolate 35 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID405110 | Antimicrobial activity against Absidia sp. assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID531234 | Antifungal activity against Candida albicans after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID564611 | Antimicrobial activity against Aspergillus fumigatus isolate 34 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572681 | Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369156 | Antifungal activity against Absidia strain 17 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID369386 | Antimicrobial activity against Rhodotorula mucilaginosa isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID563368 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID405106 | Antimicrobial activity against Rhizopus microsporus var. microsporus assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID549317 | Antifungal activity against Cunninghamella bertholletiae after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID563149 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID524013 | Cmax in high fat fed healthy human skin at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID572474 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575222 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID567429 | Antifungal activity against Dipodascus capitatus after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID563141 | Antifungal activity against Scedosporium aurantiacum CBS 116910 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID557608 | Antifungal activity against amphotericin B-resistant Aspergillus terreus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID533026 | Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on 16HBE cell after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. |
| AID563359 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID524010 | Cmax in high fat fed healthy human plasma at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID555613 | Antimicrobial activity against Aspergillus sclerotiorum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID518593 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K and C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID575348 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522452 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID580601 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 7 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID532142 | Antifungal activity against Rhizomucor species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID565397 | Antifungal activity against Rhizopus microsporus FMR 3542 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID564395 | Antimicrobial activity against Aspergillus fumigatus isolate 27 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID519469 | Antimicrobial activity against Cryptococcus albidus by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID555574 | Antimicrobial activity against Candida rugosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1309051 | Antifungal activity against Candida albicans ATCC MYA-1237 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID531215 | Antimicrobial activity against Cunninghamella bertholletiae hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID532329 | Antifungal activity against Geotrichum candidum by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID498014 | Antifungal activity against Candida tropicalis FMR 10240 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID575749 | Antimicrobial activity against sterol 14-alpha demethylase isoenzyme A-deficient Aspergillus fumigatus CEA10 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID576481 | Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID555624 | Antimicrobial activity against Scopulariopsis brevicaulis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID563405 | Antifungal activity against Aspergillus tubingensis isolate CM-4003 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID580660 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID557617 | Antifungal activity against amphotericin B-resistant Aspergillus terreus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575199 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 80 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID584407 | Antifungal activity against 7 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID572450 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID541605 | Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID525596 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID762755 | Cytotoxicity against Balb-c mouse 3T3 cells assessed as cell death at 500 umol/L by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16 | Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity. |
| AID432799 | Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro antifungal susceptibilities of five species of sporothrix. |
| AID521569 | Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed survival of the mouse at 40 mg/kg, po QD | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID555594 | Antimicrobial activity against Trichosporon dermatis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID498000 | Antifungal activity against Candida tropicalis FMR 8896 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID522444 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425367 | Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.25 ug/ml caspofungin measured at 0.5 ug/ml after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID563343 | Antifungal activity against inoculum of 1x10'4 conidia/ml Fusarium solani isolate 95-2478 after 24 hrs by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID564649 | Antimicrobial activity against Aspergillus fumigatus isolate 22 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1383457 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.17 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID508575 | Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID1419500 | Antifungal activity against Candida glabrata ATCC 2001 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID583000 | Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene in reverse orientation without doxycycline-regulatable promoter by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B. |
| AID557625 | Fungicidal activity against Aspergillus fumigatus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID425781 | Antifungal activity against Candida albicans GDH2346 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID567432 | Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID524027 | T>MIC90 in fungus infected patient skin at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID532148 | Antifungal activity against Mucor hiemalis | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522564 | Drug level in sRhizopus oryzae infected mouse serum at 40 mg/kg | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID531469 | Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring G54V, G54E, G54R and G54W mutation in cyp51A gene after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. |
| AID525544 | Antimicrobial activity against Fonsecaea nubica isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID572440 | Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522534 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID532162 | Antifungal activity against Candida glabrata by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID516343 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as abnormalities in nuclear DNA at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID575229 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID432800 | Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro antifungal susceptibilities of five species of sporothrix. |
| AID498164 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID541577 | Tmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID555579 | Antimicrobial activity against Candida intermedia by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID524011 | Cmax in high fat fed healthy human plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID580591 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID563352 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID564178 | Antimicrobial activity against Aspergillus fumigatus isolate 19 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1557088 | Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID525414 | Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 1 mg/kg/day, ip administered 24 hrs pos | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID432797 | Antifungal activity against Candida kefyr ATCC 46764 at 3 ug/ml after 14 to 18 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. |
| AID369361 | Antimicrobial activity against Candida parapsilosis blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID572211 | Cmax in fasted healthy human plasma at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID580664 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivated parasite at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post inf | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID565551 | Antifungal activity against Rhizopus microsporus IHEM 15210 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID563834 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID567448 | Antifungal activity against Trichosporon sp. after 4 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID572689 | Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID567446 | Antifungal activity against Trichosporon mucoides assessed as percent susceptible/dose-dependent isolates after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID480593 | Inhibition of rat recombinant PFT expressed in insect Sf9 cells by scintillation proximity assay | 2010 | Journal of medicinal chemistry, May-27, Volume: 53, Issue:10 | Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. |
| AID563806 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID576478 | Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID673467 | Plasma concentration in Swiss mouse at 20 mg/kg, po after 8 hrs | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID525406 | Antifungal activity against Candida glabrata isolate 4370 after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID561922 | Terminal half life in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID1265842 | Antifungal activity against azole-resistant Candida albicans MYA-1003 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran-2 | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID541588 | AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID584387 | Antifungal activity against 36 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID557809 | Drug level in patient serum with chronic graft-versus-host disease by HPLC analysis | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Posaconazole therapeutic drug monitoring: a reference laboratory experience. |
| AID582244 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID555586 | Antimicrobial activity against Saccharomyces cerevisiae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID567425 | Antifungal activity against Rhodotorula mucilaginosa after 7 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID567443 | Antifungal activity against Trichosporon asahii after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID535619 | Antifungal activity against Candida tropicalis T19 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID498002 | Antifungal activity against Candida tropicalis FMR 8898 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID581877 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx receiving antifungal drug after 23 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID728147 | Binding affinity to Trypanosoma cruzi recombinant full length CYP51 by spectrophotometric analysis | 2013 | Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6 | Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. |
| AID564168 | Antimicrobial activity against Aspergillus fumigatus isolate 9 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1487221 | Inhibition of CYP11B1 in human hepatocyte microsomes using deoxycortisol substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID498173 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID541595 | Ratio of AUC (0 to 24 hrs) in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID432801 | Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro antifungal susceptibilities of five species of sporothrix. |
| AID1265818 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID563394 | Antifungal activity against Aspergillus niger isolate CM-3641 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID673471 | Plasma concentration in Swiss mouse at 50 mg/kg, po after 24 hrs | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID547618 | Antitrypanosomal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells measured after 88 hrs postinfection by HTS assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. |
| AID563402 | Antifungal activity against Aspergillus niger isolate CM-5095 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID522451 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563139 | Antifungal activity against Scedosporium apiospermum CBS 117407 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID1419546 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-90819 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID576468 | Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID567444 | Antifungal activity against Trichosporon asahii after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID572429 | Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576260 | T>MIC90 for Aspergillus spp. infected lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID532144 | Antifungal activity against Absidia species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564405 | Antimicrobial activity against Aspergillus fumigatus isolate 37 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564390 | Antimicrobial activity against Aspergillus fumigatus isolate 22 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID555611 | Antimicrobial activity against Aspergillus ustus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID567440 | Antifungal activity against Trichosporon jirovecii after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID322856 | Antifungal activity against azole-resistant Aspergillus fumigatus V28/78-CM3275 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID572657 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572446 | Apparent total body clearance in fasted healthy human at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369388 | Antimicrobial activity against Candida africana isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID555581 | Antimicrobial activity against Candida metapsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID576440 | Cmax in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID546077 | Antifungal activity against Candida pelliculosa isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID555617 | Antimicrobial activity against Fusarium solani by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID547564 | Antifungal activity against Candida tropicalis after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID564599 | Antimicrobial activity against Aspergillus fumigatus isolate 22 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID565558 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 20 mg/kg, po BID for 5 days measured after 3 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID563381 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID1419495 | Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2876 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID535684 | Antibacterial activity against Cryptococcus gattii after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID369357 | Antimicrobial activity against Candida guilliermondii isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID555597 | Antimicrobial activity against Ustilago spp by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522435 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID285222 | Antimicrobial activity against Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID525593 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID555585 | Antimicrobial activity against Dipodascus capitatus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID518607 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID572662 | Toxicity in healthy human assessed as adverse events at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575754 | Antimicrobial activity against Aspergillus fumigatus AF293 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID525543 | Antimicrobial activity against Fonsecaea monophora isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID575358 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522493 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID438901 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in mouse 3T3 cells | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23 | Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. |
| AID581892 | Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID525541 | Antimicrobial activity against Fonsecaea isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID559691 | Antimicrobial activity against Rhizopus oryzae after 24 hrs by broth microdilution checkerboard procedure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. |
| AID560251 | Antifungal activity against Candida krusei FMR9728 by M27-A2 broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID1487219 | Inhibition of CYP2C9 in human hepatocyte microsomes using diclofenac substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID522467 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522422 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID581903 | Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID525142 | Antifungal activity against Fusarium thapsinum by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. |
| AID1898161 | Antifungal activity against Candida albicans 162 | |||
| AID555807 | Antimicrobial activity against Rhizopus oryzae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1898177 | Antifungal activity against Candida auris BS12372 | |||
| AID522473 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID557622 | Antifungal activity against Rhizopus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID581895 | Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563392 | Antifungal activity against Aspergillus niger isolate CM-3586 obtained from catheter of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID521571 | Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed as pulmonary fungal burden at 40 mg/kg, po QD | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID557615 | Antifungal activity against Cunninghamella by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID279070 | AUC (0-12 hrs) in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID1487212 | Inhibition of CYP51 in Trichophyton rubrum assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID525139 | Antifungal activity against Fusarium moniliforme clade 1 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. |
| AID584601 | Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID565561 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 40 mg/kg, po QD measured after 24 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID532041 | Antifungal activity against Lichtheimia ramosa clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID555572 | Antimicrobial activity against Candida lusitaniae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564837 | Antimicrobial activity against Aspergillus fumigatus isolate 46 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID598230 | Antimicrobial activity against Candida tropicalis isolate 11 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID730407 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as decrease in blood parasitemia level at 100 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post inf | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID425780 | Antifungal activity against Candida albicans M61 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID565568 | Antifungal activity against Rhizopus microsporus UTHSC 01-983 infected in OF1 mouse assessed as reduction in fungal load in brain at 20 mg/kg, QD for 5 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID555799 | Antimicrobial activity against Exophiala dermatitidis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522454 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID545329 | Antimicrobial activity against Candida albicans isolate R after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564632 | Antimicrobial activity against Aspergillus fumigatus isolate 5 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522497 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID555591 | Antimicrobial activity against Rhodotorula mucilaginosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID498175 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID576479 | Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1419501 | Antifungal activity against Candida krusei ATCC 6258 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID535689 | Antibacterial activity against Cryptococcus gattii serotype B after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID279201 | Antifungal activity against Aspergillus niger hyphae | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID576459 | Ratio of AUC (0 to 24 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID567333 | Antifungal activity against Saccharomyces cerevisiae after 5 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID425377 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured at 15 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID575225 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID498158 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID522704 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID542726 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 30 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID522528 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572427 | Tmax in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID673493 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 50 mg/kg, po administered 8 days after post infection qd for 5 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID508314 | Antifungal activity against Aspergillus fumigatus isolate V59-73 harboring G54W mutation in Cyp51A protein by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID1689824 | Antifungal activity against Aspergillus fumigatus ASFU77 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID564379 | Antimicrobial activity against Aspergillus fumigatus isolate 11 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID278439 | Increase in survival of Absidia corymbifera 4535 infected neutropenic CD1 mouse at 20 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID572439 | Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572475 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID394826 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes expressing beta-galactosidase in mouse 3T3 fibroblast after 7 days by alamar blue assay | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | Rational modification of a candidate cancer drug for use against Chagas disease. |
| AID519465 | Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID564638 | Antimicrobial activity against Aspergillus fumigatus isolate 11 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID498177 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID531232 | Antimicrobial activity against Cunninghamella bertholletiae hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID1383453 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.00165 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID522486 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564431 | Antimicrobial activity against Aspergillus fumigatus isolate 13 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID521969 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3608 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID1180169 | Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Design and optimization of highly-selective fungal CYP51 inhibitors. |
| AID259825 | Antiprotozoal activity against Trypanosoma cruzi amastigotes | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3 | Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. |
| AID520620 | Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID521801 | Antifungal activity against fluconazole-resistant Candida glabrata isolate 4198 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs post infection measu | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID576453 | AUC (0 to 12 hrs) in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522477 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID565555 | Antifungal activity against Rhizopus microsporus UTHSC 07-371 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1898174 | Antifungal activity against Candida krusei 467 | |||
| AID730405 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as increase in host survival at 50 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infection meas | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID531231 | Antimicrobial activity against Syncephalastrum racemosum hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID598297 | Antimicrobial activity against Candida parapsilosis isolate 39 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID532145 | Antifungal activity against Rhizopus microsporus var. oligosporus | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID547566 | Antifungal activity against Candida parapsilosis after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID555618 | Antimicrobial activity against Fusarium proliferatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1498551 | Potency index, ratio of VNI Kd(app) to compound Kd(app) for Aspergillus fumigatus CYP51 | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID1419552 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-1003 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID563374 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID564161 | Antimicrobial activity against Aspergillus fumigatus isolate 2 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID581861 | Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID673463 | Inhibition of CYP3A4/6 in human liver microsomes at 20 uM | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID283329 | Antifungal activity against Absidia spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID542724 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 60 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID563145 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID557620 | Antifungal activity against Rhizomucor hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575228 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID560480 | Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID555813 | Antimicrobial activity against Exophiala jeanselmei by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID598225 | Antimicrobial activity against Candida albicans isolate 48 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID582220 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID546068 | Antifungal activity against Candida albicans isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID567436 | Antifungal activity against Trichosporon mucoides after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID1534782 | Intrinsic clearance in human liver microsomes at 1 uM by LC-MS/MS analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID279061 | Half life in >=65 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID564523 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID508325 | Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID1062796 | Plasma concentration in Swiss mouse at 20 mg/kg, po after 0.5 hrs by LC/MS analysis | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID563365 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID535685 | Antibacterial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID564406 | Antimicrobial activity against Aspergillus fumigatus isolate 38 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575190 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID509115 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID547565 | Antifungal activity against Candida glabrata after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID518403 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220I mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID557607 | Antifungal activity against Aspergillus fumigatus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1557078 | Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID1484687 | Leishmanicidal activity against Leishmania panamensis L334 promastigotes forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID1419550 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC 1237 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564423 | Antimicrobial activity against Aspergillus fumigatus isolate 5 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572459 | Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID518605 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, E427K, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID542727 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 60 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID522407 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1557080 | Antifungal activity against Candida glabrata 192 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID582235 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID582231 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID532348 | Antifungal activity against Fusarium oxysporum by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID279075 | AUC (0-12 hrs) in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID564197 | Antimicrobial activity against Aspergillus fumigatus isolate 38 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID278446 | Reduction of number of infection foci in Rhizopus oryzae 4570 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID576443 | Ratio of AUC (0 to 12 hrs) in lung transplant recipient alveolar cell to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID582223 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID541597 | Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID535690 | Antibacterial activity against Cryptococcus gattii serotype C after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID572470 | Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563353 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID519431 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4387 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID369379 | Antimicrobial activity against Candida fermentati isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID322865 | Antifungal activity against azole-resistant Aspergillus fumigatus V49/77-CM4050 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID322858 | Antifungal activity against azole-resistant Aspergillus fumigatus V34/76-CM3277 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID572458 | Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1706420 | Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi Tulahuen strain C2C4 infected in Swiss mouse assessed as reduction in parasitemia at 20 mg/kg, po qd administered for 20 days starting from day 8 post infection follow | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID1557075 | Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID1817557 | Antifungal activity against Aspergillus fumigatus ATCC 204305 assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections. |
| AID1557084 | Antifungal activity against Candida dubliniensis T-99 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID498170 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532349 | Antifungal activity against Sporothrix schenckii by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID576487 | Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1419493 | Antifungal activity against Candida albicans ATCC 10231 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID369389 | Antimicrobial activity against Trichosporon isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID584587 | Antifungal activity against 111 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564839 | Antimicrobial activity against Aspergillus fumigatus isolate 48 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584396 | Antifungal activity against 13 days cultured Candida krusei isolated from invasive fungal infected subject blood after 12 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID560475 | Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID561920 | Apparent oral clearance in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564408 | Antimicrobial activity against Aspergillus fumigatus isolate 40 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572460 | Half life in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID425800 | Antifungal activity against Candida parapsilosis PA/71 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID557614 | Antifungal activity against Mucor by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID598228 | Antimicrobial activity against Candida krusei isolate 48 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID555812 | Antimicrobial activity against Saksenaea vasiformis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID581873 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool receiving antifungal drug after 22 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID518609 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, L358L, E427K, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID519428 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3599 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID432795 | Antifungal activity against Candida kefyr ATCC 46764 at 0.5 ug/ml after 14 to 18 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. |
| AID563416 | Antifungal activity against Aspergillus niger isolate CM-4262 after 48 hrs by EUCAST broth dilution method Ophthalmic | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID522550 | Antifungal activity against drug-susceptible Rhizopus oryzae infected in OF1 mouse assessed as mouse survival at 30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522525 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1265817 | Antifungal activity against azole-resistant Candida albicans ATCC 90819 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID522494 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID524738 | Antimicrobial activity against Fusarium proliferatum after 48 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. |
| AID1419574 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus terreus ATCC MYA-3633 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID279072 | Apparent total clearance in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID541611 | Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID557621 | Antifungal activity against Absidia hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564202 | Antimicrobial activity against Aspergillus fumigatus isolate 43 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1898226 | Cytotoxicity against human Caco-2 cells assessed as cell viability at 64 ug/ml incubated for 24 hrs by CCK-8 assay | |||
| AID567434 | Antifungal activity against Saccharomyces cerevisiae after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID405109 | Antimicrobial activity against Rhizomucor sp. assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID285223 | Antimicrobial activity against Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID581883 | Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1587054 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 12.5 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and m | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. |
| AID522544 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID509392 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse body weight at 20 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID1419573 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus terreus ATCC MYA-3633 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID584400 | Antifungal activity against 35 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 165 days after 138 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID581866 | Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID405097 | Antimicrobial activity against Absidia sp. after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID405103 | Antimicrobial activity against Rhizopus sp. assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID598298 | Antimicrobial activity against Candida parapsilosis isolate 44 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID1898175 | Antifungal activity against Candida glabrata ATCC2001 | |||
| AID525597 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID557609 | Antifungal activity against Aspergillus flavus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575353 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID572688 | Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID518612 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A E130D mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID564167 | Antimicrobial activity against Aspergillus fumigatus isolate 8 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564669 | Antimicrobial activity against Aspergillus fumigatus isolate 42 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283336 | Antifungal activity against Rhizopus spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID555584 | Antimicrobial activity against Candida zeylanoides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522442 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572690 | Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD and diarrhea | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563349 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID673486 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase of host survival at 2 mg/kg, po administered 8 days after post infection qd for 5 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID565400 | Antifungal activity against Rhizopus microsporus IHEM 13267 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID547568 | Antifungal activity against Candida dubliniensis after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID531228 | Antimicrobial activity against Rhizopus spp. hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID1595044 | Antifungal activity against Cryptococcus neoformans LA314 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID576495 | AUC (0 to 12 hrs) in healthy human epithelial lining fluid at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID519466 | Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID564617 | Antimicrobial activity against Aspergillus fumigatus isolate 40 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572477 | Apparent volume of distribution in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522553 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522543 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425163 | Antifungal activity against Candida glabrata isolate 4205 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID564173 | Antimicrobial activity against Aspergillus fumigatus isolate 14 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522479 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID519429 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4330 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID531235 | Antifungal activity against Candida glabrata after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID531222 | Antimicrobial activity against Rhizopus spp. conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID567437 | Antifungal activity against Trichosporon inkin after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID532129 | Antifungal activity against Candida lusitaniae | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID572691 | Cmax in plasma in hematopoietic stem cell transplant recipient human with GVHD | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532319 | Antifungal activity against Candida parapsilosis by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1184056 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigotes expressing green florescent protein infected in cardiomyocytes assessed as inhibition of parasite growth at 10 nM after 72 hrs by fluorescence microscopy | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition. |
| AID563361 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID425372 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured at 5 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID598293 | Antimicrobial activity against Candida glabrata isolate 32 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID1062774 | Toxicity in Swiss mouse at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID555616 | Antimicrobial activity against Penicillium spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID563344 | Antifungal activity against inoculum of 1x10'4 conidia/ml Fusarium solani isolate 95-2478 after 48 hrs by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID545663 | Cellular uptake in PMNC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID546080 | Antifungal activity against Candida pulcherrima isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID567426 | Antifungal activity against Rhodotorula mucilaginosa after 7 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID1309058 | Antifungal activity against Aspergillus terreus ATCC MYA3633 after 48 hrs by CLSI M38-A2 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID1309053 | Antifungal activity against Candida glabrata ATCC 2001 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID584399 | Antifungal activity against 59 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID565567 | Antifungal activity against Rhizopus microsporus IHEM 4770 infected in OF1 mouse assessed as reduction in fungal load in brain at 20 mg/kg, QD for 5 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID555589 | Antimicrobial activity against Cryptococcus neoformans var. neoformans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID572483 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1706433 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID555593 | Antimicrobial activity against Trichosporon ovoides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID581865 | Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth receiving antifungal drug after 115 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563366 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID582254 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID283339 | Antifungal activity against Syncephalastrum spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID572428 | Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369163 | Antifungal activity against Mucor strain 43 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID572672 | Toxicity in healthy human assessed as dizziness at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID555567 | Antimicrobial activity against Candida parapsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID572454 | Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564207 | Antimicrobial activity against Aspergillus fumigatus isolate 48 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575355 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID425368 | Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.015 ug/ml caspofungin measured at 4 ug/ml measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID522515 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID535620 | Antifungal activity against Candida tropicalis T26 blood stream isolate harboring Fks1p LLTLSLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID555615 | Antimicrobial activity against Aspergillus spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555811 | Antimicrobial activity against Rhizomucor spp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID545151 | Antimicrobial activity against Candida albicans isolate R after 48 hrs by EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564373 | Antimicrobial activity against Aspergillus fumigatus isolate 5 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1265821 | Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID278469 | Percentage of infected spleen in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID1595050 | Antifungal activity against Aspergillus niger assessed as reduction in fungal cell growth incubated for 72 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID546073 | Antifungal activity against Candida tropicalis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID563415 | Antifungal activity against Aspergillus foetidus isolate CM-4002 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID555605 | Antimicrobial activity against Aspergillus flavus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID561911 | AUClast in healthy human at 400 mg/kg, po by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID520618 | Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID572679 | Toxicity in healthy human assessed as asthenia at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564432 | Antimicrobial activity against Aspergillus fumigatus isolate 14 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID555612 | Antimicrobial activity against Aspergillus niveus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID565566 | Antifungal activity against Rhizopus microsporus IHEM 4770 infected in OF1 mouse assessed as reduction in fungal load in brain at 40 mg/kg, QD for 5 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1062803 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as cure rate at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of immunosup | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID522556 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564380 | Antimicrobial activity against Aspergillus fumigatus isolate 12 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522502 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID547546 | Antifungal activity against Cryptococcus gattii after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID557632 | Fungicidal activity against Mucor | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID498149 | Antifungal activity against Candida tropicalis FMR 10236 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID545668 | Ratio of intracellular to extracellular cellular uptake in RBC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID575197 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 40 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID521792 | Fungistatic activity against Candida glabrata isolate 4293 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID278463 | Percentage of infected brain in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID283330 | Antifungal activity against Cunninghamella spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID522458 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID730420 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI extracellular trypomastigotes forms transfected with beta-galactosidase gene infected in rat L6 cells assessed as inhibition of parasite growth after 4 days | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID405108 | Antimicrobial activity against Mucor circinelloides assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID565564 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 20 mg/kg, po BID for 5 days measured after 24 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID278438 | Increase in survival of Rhizopus oryzae 4570 infected neutropenic CD1 mouse at 80 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID564614 | Antimicrobial activity against Aspergillus fumigatus isolate 37 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID581880 | Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth after 124 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID369362 | Antimicrobial activity against Candida tropicalis blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID369384 | Antimicrobial activity against Candida palmioleophila isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID555569 | Antimicrobial activity against Candida glabrata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID572215 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID555808 | Antimicrobial activity against Mucor spp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564206 | Antimicrobial activity against Aspergillus fumigatus isolate 47 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283331 | Antifungal activity against Cunninghamella spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID1534783 | Kinetic solubility of compound in pH 7.4 PBS by LC-MS/MS analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID572452 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1498549 | Binding affinity to Aspergillus fumigatus CYP51 by spectral titration method | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID522468 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541601 | Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522478 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564201 | Antimicrobial activity against Aspergillus fumigatus isolate 42 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID425371 | Antifungal activity against Candida glabrata isolate 4293 at 15 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID584404 | Antifungal activity against 3 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID518597 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q88H mutant gene and by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID564662 | Antimicrobial activity against Aspergillus fumigatus isolate 35 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID425788 | Antifungal activity against Candida parapsilosis PA/71 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID563403 | Antifungal activity against Aspergillus tubingensis isolate CM-3123 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID508587 | Antifungal activity against Aspergillus fumigatus isolate V59-73 harboring G54W mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID555622 | Antimicrobial activity against Paecilomyces lilacinus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID563414 | Antifungal activity against Aspergillus tubingensis isolate CM-4001 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID582218 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID545666 | Ratio of intracellular to extracellular cellular uptake in PBMC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID518613 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A L252L mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID575071 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 80 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1171001 | Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as increase in lanosterol level at 100 nM incubated for 24 hrs by GC-MS method | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. |
| AID555568 | Antimicrobial activity against Candida tropicalis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509395 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 40 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID529667 | Antimicrobial activity against Paecilomyces variotii by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Susceptibility testing and molecular classification of Paecilomyces spp. |
| AID576463 | Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID557616 | Antifungal activity against Aspergillus fumigatus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564160 | Antimicrobial activity against Aspergillus fumigatus isolate 1 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID279197 | Antifungal activity against Aspergillus niger conidia | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1265841 | Antifungal activity against azole-resistant Candida albicans MYA-1237 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran-2 | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID531233 | Antifungal activity against Candida tropicalis after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID581889 | Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth receiving antifungal drug after 109 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522511 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563387 | Antifungal activity against Aspergillus niger isolate CM-3236 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID598299 | Antimicrobial activity against Candida parapsilosis isolate 19 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID549321 | Antifungal activity against Rhizomucor pusillus after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID519445 | Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-2270 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID572677 | Toxicity in healthy human assessed as asthenia at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID541617 | Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID572435 | Tmax in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563398 | Antifungal activity against Aspergillus tubingensis isolate CM-4264 obtained from blood culture after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID555590 | Antimicrobial activity against Trichosporon asahii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID532046 | Antifungal activity against Lichtheimia ornata clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID498006 | Antifungal activity against Candida tropicalis FMR 10232 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID581901 | Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID509107 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID369371 | Antimicrobial activity against Candida parapsilosis isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID522474 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522434 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID555601 | Antimicrobial activity against Trichosporon mycotoxinivorans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID369153 | Antifungal activity against Rhizopus strain 3 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID582242 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID509394 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 20 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID563794 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID518401 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G138C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID1557085 | Antifungal activity against Candida albicans ATCC 90028 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID322857 | Antifungal activity against azole-resistant Aspergillus fumigatus V34/75-CM3276 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID1265816 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID582216 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID519549 | Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-2280 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID581907 | Ratio of CDR2 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to CDR2 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564619 | Antimicrobial activity against Aspergillus fumigatus isolate 42 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584600 | Antifungal activity against 16 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID369360 | Antimicrobial activity against Candida glabrata blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID498193 | Drug level in patient undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID547353 | Antifungal activity against Candida lusitaniae after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID567431 | Antifungal activity against Rhodotorula mucilaginosa after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID369152 | Antifungal activity against Rhizopus strain 0 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID1265839 | Antifungal activity against azole-resistant Candida albicans ATCC 90819 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID532341 | Antifungal activity against Mucor species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID567439 | Antifungal activity against Trichosporon jirovecii after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID545667 | Ratio of intracellular to extracellular cellular uptake in PMNC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID541596 | Ratio of AUC (0 to 24 hrs) in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID576448 | Tmax in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522519 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541586 | Tmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID563364 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID582233 | Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID581911 | Ratio of CDR2 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to CDR2 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID584408 | Antifungal activity against 10 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 37 days after 9 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563380 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID563805 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID541616 | Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID369376 | Antimicrobial activity against Candida guilliermondii isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID547620 | Antitrypanosomal activity against Trypanosoma cruzi PSD-I infected in BESM cells measured after 88 hrs postinfection by HTS assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. |
| AID564656 | Antimicrobial activity against Aspergillus fumigatus isolate 29 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1898169 | Antifungal activity against Candida tropicalis 112936 | |||
| AID498182 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID557628 | Fungicidal activity against Aspergillus niger | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID535686 | Antibacterial activity against Cryptococcus neoformans serotype A after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID555602 | Antimicrobial activity against Trichosporon spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1689823 | Antifungal activity against Aspergillus fumigatus ASFU7 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID564640 | Antimicrobial activity against Aspergillus fumigatus isolate 13 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564515 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID518615 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID498005 | Antifungal activity against Candida tropicalis FMR 10231 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564506 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID278457 | Reduction of infection foci size in Absidia corymbifera 4535 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID572653 | Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID555599 | Antimicrobial activity against Cryptococcus laurentii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID516322 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as abnormalities in nuclear DNA at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID575204 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID259830 | Disruption of calcium homeostasis in Trypanosoma cruzi | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3 | Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. |
| AID582253 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID532140 | Antifungal activity against Aspergillus flavus | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID547619 | Antitrypanosomal activity against Trypanosoma cruzi Sylvio-X10/7 infected in BESM cells measured after 88 hrs postinfection by HTS assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. |
| AID1487217 | Inhibition of CYP51 in Cryptococcus neoformans assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID498145 | Antifungal activity against Candida tropicalis FMR 10232 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID516337 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as reduction in episterol content at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID564628 | Antimicrobial activity against Aspergillus fumigatus isolate 1 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1898178 | Antifungal activity against Candida auris 887 | |||
| AID564600 | Antimicrobial activity against Aspergillus fumigatus isolate 23 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563377 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID279054 | Tmax in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID555570 | Antimicrobial activity against Candida krusei by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID541604 | Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID555603 | Antimicrobial activity against Aspergillus fumigatus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID369392 | Antimicrobial activity against Trichosporon inkin isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1419566 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida albicans ATCC 10231 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID369367 | Antimicrobial activity against Candida guilliermondii blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID521568 | Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed survival of the mouse at 40 mg/kg, po QD | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID1557095 | Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID572442 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID581867 | Antifungal activity against Candida albicans isolated from HSCT recipient 301 with acute or chronic GVHD mouth receiving antifungal drug after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1706436 | Inhibition of Trypanosoma cruzi Tulahuen C4 strain CYP51 expressed in Escherichia coli by fluorescence based assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID532340 | Antifungal activity against Mucor hiemalis by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID572466 | Half life in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID541875 | Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID576456 | Ratio of Cmax in lung transplant recipient plasma after 12 hrs to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID580662 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of low level of circulating parasites at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 25 days p | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID542418 | Antimicrobial activity against Aspergillus terreus environmental isolate after 48 hrs by EUCAST test | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. |
| AID498165 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564027 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID531219 | Antimicrobial activity against Absidia corymbifera hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID581888 | Antifungal activity against Candida albicans isolated from HSCT recipient 031 with acute or chronic GVHD mouth after 109 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID531226 | Antimicrobial activity against Cunninghamella bertholletiae conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID584596 | Antifungal activity against 177 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID498167 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID1817568 | Antifungal activity against pan-azole resistant Aspergillus fumigatus SR47013 harbouring Cyp51A Y121F mutant assessed as inhibition of fungal growth incubated for 24 hrs by broth microdilution method | 2021 | Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14 | Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections. |
| AID555600 | Antimicrobial activity against Trichosporon domesticum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555810 | Antimicrobial activity against Rhizopus microsporus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1419505 | Antifungal activity against Aspergillus terreus ATCC MYA-3633 incubated for 48 hrs by CLSI M38-A2 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID531237 | Antifungal activity against Candida guilliermondii after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID375464 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected BALB/c mouse model of acute Chagas disease assessed as parasitemia burden in blood at 20 mg/kg, po administered twice daily 7 days after parasite infection for 21 days measured 100 days | 2009 | Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12 | Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. |
| AID572670 | Toxicity in healthy human assessed as dizziness at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID480595 | Inhibition of human recombinant CYP3A4 | 2010 | Journal of medicinal chemistry, May-27, Volume: 53, Issue:10 | Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. |
| AID531210 | Antimicrobial activity against Rhizopus oryzae conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID561916 | AUC (0 to infinity) in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564419 | Antimicrobial activity against Aspergillus fumigatus isolate 1 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID519447 | Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3914 obtained from nail of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID369390 | Antimicrobial activity against Candida famata isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1595046 | Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID518614 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A S400I mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID564838 | Antimicrobial activity against Aspergillus fumigatus isolate 47 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1684560 | Antifungal activity against Mucor circinelloides ATCC 26579 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID508331 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID572424 | AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID541896 | Cardiotoxicity in healthy human assessed as corrected QT intervals at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID535618 | Antifungal activity against Candida tropicalis T3 blood stream isolate harboring Fks1p FLTLS/PLRDP mutant protein | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID563393 | Antifungal activity against Aspergillus niger isolate CM-3636 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID557612 | Antifungal activity against Absidia by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1383458 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.5 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID1898167 | Antifungal activity against Candida parapsilosis 90018 | |||
| AID555627 | Antimicrobial activity against Hormographiella aspergillata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID563363 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID524026 | T>MIC90 in fungus infected patient skin at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID564601 | Antimicrobial activity against Aspergillus fumigatus isolate 24 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564438 | Antimicrobial activity against Aspergillus fumigatus isolate 20 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564424 | Antimicrobial activity against Aspergillus fumigatus isolate 6 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID369349 | Antimicrobial activity against Candida albicans isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID524030 | Ratio of AUC in skin to plasma in healthy human at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID567433 | Antifungal activity against Saccharomyces cerevisiae after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID581898 | Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth after 116 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID567441 | Antifungal activity against Trichosporon domesticum after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID567442 | Antifungal activity against Trichosporon domesticum after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID563370 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID524029 | Toxicity in healthy human assessed as treatment related treatment-emergent adverse events at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID564381 | Antimicrobial activity against Aspergillus fumigatus isolate 13 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563144 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID522520 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID581868 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool after 26 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID555583 | Antimicrobial activity against Candida pintolopesii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1882559 | Inhibition of recombinant Trypanosoma cruzi Tulahuen strain CYP51 expressed in Escherichia coli JM109 | 2022 | Bioorganic & medicinal chemistry, 03-15, Volume: 58 | Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease. |
| AID555805 | Antimicrobial activity against Lecythophora hoffmannii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID509100 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in OF1 mouse assessed as increase in mouse survival at 20 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID576465 | Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID279069 | Tmax in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID279043 | Cmax in >=65 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID560468 | Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID498357 | Apparent oral clearance in patient with diarrhea undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID532131 | Antifungal activity against Candida guilliermondii | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564166 | Antimicrobial activity against Aspergillus fumigatus isolate 7 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID518602 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID580584 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID564392 | Antimicrobial activity against Aspergillus fumigatus isolate 24 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1265846 | Antifungal activity against azole-resistant Candida albicans ATCC 90819 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID576466 | Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID572209 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522416 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID549327 | Antifungal activity against Actinomucor spp. after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID516335 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as reduction in fecosterol content at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID555576 | Antimicrobial activity against Candida pelliculosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID532342 | Antifungal activity against Cunninghamella species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575196 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 20 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID555058 | Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 10281 infected in immunosuppressed-OF1 mouse assessed as prolonged survival of mouse at 100 mg/kg, po administered 1 day post infection measured 20 days post bacterial infection | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID279055 | AUC (0-12 hrs) in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID555866 | Antimicrobial activity against Beauveria bassiana by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1898152 | Antifungal activity against Aspergillus fumigatus 7544 incubated for 48 hrs by microbroth dilution method | |||
| AID532325 | Antifungal activity against Cryptococcus neoformans var. neoformans by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522471 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2457 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1484684 | Leishmanicidal activity against Leishmania mexicana 68 promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID1419570 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus flavus ATCC MYA-3631 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID557630 | Fungicidal activity against Absidia | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555796 | Antimicrobial activity against Scedosporium prolificans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582229 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522523 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498155 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID555614 | Antimicrobial activity against Aspergillus glaucus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID575346 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID560457 | Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID564660 | Antimicrobial activity against Aspergillus fumigatus isolate 33 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID532130 | Antifungal activity against Candida tropicalis | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555610 | Antimicrobial activity against Aspergillus ochraceus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1383452 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.0005 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID498007 | Antifungal activity against Candida tropicalis FMR 10333 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID580580 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID522431 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID555578 | Antimicrobial activity against Candida norvegensis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID508583 | Ratio of AUC to MIC for wild type Aspergillus fumigatus infected in CD1 mouse | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID425375 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of caspofungin MIC measured at 15 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID555607 | Antimicrobial activity against Aspergillus nidulans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID560252 | Antifungal activity against Candida krusei FMR9729 by M27-A2 broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID576458 | Cmax in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522529 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID524025 | T>MIC90 in fungus infected patient plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID525140 | Antifungal activity against Fusarium moniliforme clade 2 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. |
| AID555596 | Antimicrobial activity against Cryptococcus albidus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1487213 | Inhibition of CYP51 in Candida albicans assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID369391 | Antimicrobial activity against Trichosporon asahii isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID522397 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID582228 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID576455 | Cmin in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522456 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID532135 | Antifungal activity against Trichosporon inkin | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID576452 | AUC (0 to 24 hrs) in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID584391 | Antifungal activity against 16 days cultured Candida glabrata isolated from invasive fungal infected subject blood after 17 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1265820 | Antifungal activity against azole-resistant Candida albicans MYA-1003 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID508311 | Antifungal activity against Aspergillus fumigatus isolate AZN 8196 harboring wild type Cyp51A protein by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID522463 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID279050 | AUC (0-12 hrs) in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID567430 | Antifungal activity against Dipodascus capitatus after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID563829 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID576451 | Ratio of AUC (0 to 12 hrs) in lung transplant recipient epithelial lining fluid to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID555275 | Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 10281 infected in immunosuppressed-OF1 mouse assessed as reduction in spleen fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID564371 | Antimicrobial activity against Aspergillus fumigatus isolate 3 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID565556 | Antifungal activity against Rhizopus microsporus UTHSC 01-983 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID572663 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1557096 | Ratio of MIC for Candida glabrata ATCC 66032 after 48 hrs to MIC for Candida glabrata ATCC 66032 after 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID369350 | Antimicrobial activity against Candida glabrata isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID564631 | Antimicrobial activity against Aspergillus fumigatus isolate 4 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID542728 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as reduction of fungal burden in kidneys at 60 mg/kg/day, po administered 8 hrs post infection for 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID1419498 | Antifungal activity against ITC and FLC-resistant Candida albicans ATCC 1237 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564503 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID564401 | Antimicrobial activity against Aspergillus fumigatus isolate 33 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563581 | Metabolic stability in healthy human plasma assessed as compound recovery at 6 mg/kg BID | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. |
| AID598231 | Antimicrobial activity against Candida tropicalis isolate 15 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID575203 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522413 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522403 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID582219 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564428 | Antimicrobial activity against Aspergillus fumigatus isolate 10 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID279064 | Tmax in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID1419551 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-1003 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID525542 | Antimicrobial activity against Fonsecaea pedrosoi isolates after 72 hrs by CLSI M38-A2 protocol method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. |
| AID575371 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID555571 | Antimicrobial activity against Candida guilliermondii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID563401 | Antifungal activity against Aspergillus tubingensis isolate CM-5094 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID555625 | Antimicrobial activity against Trichoderma spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID369355 | Antimicrobial activity against Candida kefyr isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID279199 | Antifungal activity against Aspergillus terreus hyphae | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID369353 | Antimicrobial activity against Cryptococcus neoformans isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID563383 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID555628 | Antimicrobial activity against Fusarium equiseti by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564603 | Antimicrobial activity against Aspergillus fumigatus isolate 26 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522450 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID576496 | AUC (0 to 12 hrs) in healthy human alveolar cell at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522421 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498184 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID498139 | Antifungal activity against Candida tropicalis FMR 8896 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID563801 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID546071 | Antifungal activity against Clavispora lusitaniae isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID567427 | Antifungal activity against Dipodascus capitatus after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID555623 | Antimicrobial activity against Acremonium sp.by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1062778 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of immunosuppression measured on d | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID525411 | Fungistatic activity against Candida parapsilosis ATCC 22019 assessed as 99.9% reduction of int initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID563412 | Antifungal activity against Aspergillus tubingensis isolate CM-3654 obtained from blood culture after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID582247 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564417 | Antimicrobial activity against Aspergillus fumigatus isolate 49 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564665 | Antimicrobial activity against Aspergillus fumigatus isolate 38 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID322862 | Antifungal activity against azole-resistant Aspergillus fumigatus V45/07-CM3819 isolate from patient with chronic granulomatous disease by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID575755 | Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme B expressed in Escherichia coli assessed as tight binding affinity constant | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID1484683 | Leishmanicidal activity against Leishmania major KK promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID522503 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1833887 | Inhibition of Naegleria fowleri CYP51 catalytic activity using [3-3H]sterol substrate measured after 1 hr by RP-HPLC analysis | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23 | Relaxed Substrate Requirements of Sterol 14α-Demethylase from |
| AID572465 | Half life in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576447 | Ratio of Cmax in lung transplant recipient epithelial lining fluid after 12 hrs to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID283335 | Antifungal activity against Rhizomucor spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID498159 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID369359 | Antimicrobial activity against Candida albicans blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID584397 | Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID480594 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in rat 3T3 cells after 7 days by alamar blue assay | 2010 | Journal of medicinal chemistry, May-27, Volume: 53, Issue:10 | Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. |
| AID278467 | Percentage of infected lung in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID530559 | Antimicrobial activity against Aspergillus fumigatus isolate DK infected in NMRI mouse assessed as survival rate at 20 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. |
| AID519468 | Antimicrobial activity against Cryptococcus gattii by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID563142 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID541574 | Cmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID498168 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID575495 | Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 by EUCAST microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID519440 | Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3305 obtained from skin of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID524012 | Cmax in high fat fed healthy human skin at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID564393 | Antimicrobial activity against Aspergillus fumigatus isolate 25 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1383455 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.0165 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID279049 | Tmax in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID1898150 | Antifungal activity against Cryptococcus neoformans H99 incubated for 72 hrs by microbroth dilution method | |||
| AID555802 | Antimicrobial activity against Cladosporium spp. by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID508324 | Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID524739 | Antimicrobial activity against Fusarium oxysporum after 48 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. |
| AID519467 | Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID576444 | AUC (0 to 12 hrs) in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID541878 | T>MIC90 in healthy human plasma at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522517 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541589 | AUC (0 to 12 hrs) in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID563391 | Antifungal activity against Aspergillus tubingensis isolate CM-3585 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID557627 | Fungicidal activity against Aspergillus flavus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID279076 | Half life in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID279058 | Cmax in >=65 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID555629 | Antimicrobial activity against Fusarium reticulatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555801 | Antimicrobial activity against Hortaea werneckii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID533028 | Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as planktonic cell on CFBE41o cell after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. |
| AID564164 | Antimicrobial activity against Aspergillus fumigatus isolate 5 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID549310 | Antifungal activity against Rhizopus oryzae after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID522411 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID584403 | Antifungal activity against 1 day cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID581893 | Antifungal activity against Candida albicans isolated from HSCT recipient 042 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID531224 | Antimicrobial activity against Mucor spp. conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID582222 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1487220 | Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID564374 | Antimicrobial activity against Aspergillus fumigatus isolate 6 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1419542 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida albicans ATCC 64124 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564625 | Antimicrobial activity against Aspergillus fumigatus isolate 48 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564616 | Antimicrobial activity against Aspergillus fumigatus isolate 39 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584412 | Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID547567 | Antifungal activity against Candida krusei after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID557610 | Antifungal activity against Aspergillus niger by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID509099 | Antifungal activity against Fonsecaea monophora CBS 117236 | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID425787 | Antifungal activity against Candida albicans GDH2346 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID555274 | Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 5205 infected in immunosuppressed-OF1 mouse assessed as reduction in kidney fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID555575 | Antimicrobial activity against Candida famata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582246 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID532154 | Antifungal activity against Penicillium species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519470 | Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID522536 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564192 | Antimicrobial activity against Aspergillus fumigatus isolate 33 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID673469 | Plasma concentration in Swiss mouse at 50 mg/kg, po after 1 hr | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID576483 | Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1265845 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiom | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID525595 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID279044 | Tmax in >=65 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID541876 | T>MIC90 in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID572443 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572665 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID285220 | Effect on survival in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID531225 | Antimicrobial activity against Syncephalastrum racemosum conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID582230 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID498358 | Apparent volume of distribution in patient without diarrhea undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID532125 | Antifungal activity against Candida albicans | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555800 | Antimicrobial activity against Aureobasidium pullulans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID582251 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID671571 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 20 mg/kg, po administered 8 day after post infection qd for 20 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID565402 | Antifungal activity against Rhizopus microsporus IHEM 10123 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID564186 | Antimicrobial activity against Aspergillus fumigatus isolate 27 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1595047 | Antifungal activity against Candida krusei assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID508317 | AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID584418 | Antifungal activity against 62 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID509114 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in brain compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID547545 | Antifungal activity against Cryptococcus neoformans after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID572479 | Apparent volume of distribution in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1689822 | Antifungal activity against Aspergillus fumigatus ASFU76 assessed as reduction in microbial growth after 48 hrs by resazurin staining based spectrofluorometric method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID549315 | Antifungal activity against Mycocladus corymbifer after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID521793 | Fungistatic activity against Candida parapsilosis ATCC 22019 assessed as 99.9% reduction of int initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID1419497 | Antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2310 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID584594 | Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID581891 | Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID532155 | Antifungal activity against Fusarium solani | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1474110 | AUC in human at 200 mg, po TID after 8 hrs | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID279200 | Antifungal activity against Aspergillus flavus hyphae | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID555577 | Antimicrobial activity against Candida coliculosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID369363 | Antimicrobial activity against Cryptococcus neoformans blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID369373 | Antimicrobial activity against Cryptococcus neoformans isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID584393 | Antifungal activity against 1 day cultured Candida albicans isolated from HSCT recipient with acute or chronic GVHD mouth after 2 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID369161 | Antifungal activity against Mucor strain 28 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID1557077 | Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID518606 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, L358L, E427K, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID564189 | Antimicrobial activity against Aspergillus fumigatus isolate 30 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID542417 | Antimicrobial activity against Aspergillus terreus clinical isolate after 48 hrs by EUCAST test | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. |
| AID582238 | Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1706421 | Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi Tulahuen strain C2C4 infected in Swiss mouse assessed as reduction in parasitemia at 20 mg/kg, po qd administered for 20 days starting from day 8 post infection and me | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID546072 | Antifungal activity against Candida glabrata isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID531207 | Antimicrobial activity against Rhizomucor spp. conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID498179 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID369369 | Antimicrobial activity against Candida albicans isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID519439 | Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3303 obtained from skin of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID1898159 | Antifungal activity against Candida albicans 12# | |||
| AID1419544 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2876 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564181 | Antimicrobial activity against Aspergillus fumigatus isolate 22 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564397 | Antimicrobial activity against Aspergillus fumigatus isolate 29 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575351 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1062788 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 20 mg/kg, po qd administered on day 8 post-infection measured on same day by microscopic analysis | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID555608 | Antimicrobial activity against Aspergillus sydowii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564620 | Antimicrobial activity against Aspergillus fumigatus isolate 43 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1477763 | Antifungal activity against drug resistant Candida albicans DF2672R after 24 hrs by two fold serial dilution method | 2017 | Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24 | Semisynthesis and Biological Evaluation of Xanthone Amphiphilics as Selective, Highly Potent Antifungal Agents to Combat Fungal Resistance. |
| AID369378 | Antimicrobial activity against Candida haemulonii isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID519464 | Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. |
| AID555598 | Antimicrobial activity against Rhodotorula glutinis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID565559 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 40 mg/kg, po QD for 5 days measured after 3 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1684561 | Antifungal activity against Fusarium solani ATCC 58877 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID498162 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID563350 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID522408 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572445 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID518599 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, Q141H mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID559895 | Plasma concentration in patient with Aspergillus infection at 600 to 800 mg/kg/day | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. |
| AID525601 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID522548 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID533025 | Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on 16HBE cell after 24 to 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. |
| AID522647 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-3165 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522540 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID584388 | Antifungal activity against 42 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522443 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425364 | Antifungal activity against Candida glabrata isolate 4370 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID278465 | Percentage of infected lung in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID557633 | Fungicidal activity against Cunninghamella | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522439 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564383 | Antimicrobial activity against Aspergillus fumigatus isolate 15 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID369372 | Antimicrobial activity against Candida tropicalis isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1171002 | Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as increase in eburicol level at 100 nM incubated for 24 hrs by GC-MS method | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. |
| AID1898151 | Antifungal activity against Candida albicans SC5314 incubated for 24 hrs by microbroth dilution method | |||
| AID564025 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID572423 | AUC in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522438 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1487216 | Inhibition of CYP51 in Candida glabrata assessed as inhibition of microbe growth incubated for 48 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID522537 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1898162 | Antifungal activity against Candida albicans 14# | |||
| AID405101 | Antimicrobial activity against Cunninghamella sp. after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID509391 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse body weight at 10 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID1898166 | Antifungal activity against Candida parapsilosis 660 | |||
| AID1484685 | Leishmanicidal activity against Leishmania mexicana 390 promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID582221 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID546078 | Antifungal activity against Candida kefyr isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID535688 | Antibacterial activity against Cryptococcus neoformans serotype AD after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID508320 | Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID549326 | Antifungal activity against Actinomucor spp. after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID582217 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1265837 | Antifungal activity against azole-resistant Candida albicans ATCC 64124 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID581874 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx after 61 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID508329 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID575356 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID581864 | Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool after 48 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID549325 | Antifungal activity against Cunninghamella spp. after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID565569 | Antifungal activity against Rhizopus microsporus UTHSC R-3466 infected in OF1 mouse assessed as reduction in fungal load in kidney at 20 mg/kg, QD for 5 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID563395 | Antifungal activity against Aspergillus niger isolate CM-3672 obtained from cutaneous layer of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID279065 | AUC (0-12 hrs) in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID519446 | Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-4060 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID1062794 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as reduction in blood parasitemia at 20 mg/kg, po qd administered on day 8 post-infection for 10 days by microscopic analysis | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID532159 | Antifungal activity against Bipolaris australiensis | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID508319 | Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID283337 | Antifungal activity against Rhizopus spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID564369 | Antimicrobial activity against Aspergillus fumigatus isolate 1 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572481 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576474 | Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID564633 | Antimicrobial activity against Aspergillus fumigatus isolate 6 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522485 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564651 | Antimicrobial activity against Aspergillus fumigatus isolate 24 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID278473 | Percentage of infected kidney in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID564177 | Antimicrobial activity against Aspergillus fumigatus isolate 18 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564643 | Antimicrobial activity against Aspergillus fumigatus isolate 16 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522430 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3580 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID581869 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1102 with AML or MDS stool receiving antifungal drug after 26 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1557082 | Antifungal activity against Candida parapsilosis ATCC 22019 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID564378 | Antimicrobial activity against Aspergillus fumigatus isolate 10 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563351 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID576467 | Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID561918 | AUClast in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564664 | Antimicrobial activity against Aspergillus fumigatus isolate 37 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564426 | Antimicrobial activity against Aspergillus fumigatus isolate 8 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563814 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID564179 | Antimicrobial activity against Aspergillus fumigatus isolate 20 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564367 | Antimicrobial activity against Aspergillus fumigatus isolate 49 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID425378 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of amphotericin B MIC measured at 5 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID530564 | Antimicrobial activity against Aspergillus fumigatus isolate AT infected in NMRI mouse assessed as survival rate at 20 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. |
| AID575492 | Antifungal activity against azole-resistant Aspergillus fumigatus isolate T22 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 0.5 mg/l relative to control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID535687 | Antibacterial activity against Cryptococcus neoformans serotype D after 72 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. |
| AID1419502 | Antifungal activity against Candida parapsilosis ATCC 22019 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID522426 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522522 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID279059 | Tmax in >=65 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID557619 | Antifungal activity against Aspergillus niger hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575207 | Antifungal activity against Cunninghamella echinulata FMR 10973 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID425159 | Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID563382 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID279038 | Cmax in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID531239 | Antifungal activity against Candida lusitaniae after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID546074 | Antifungal activity against Candida dubliniensis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID582245 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563410 | Antifungal activity against Aspergillus tubingensis isolate CM-3177 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID285224 | Antimicrobial activity against Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID369351 | Antimicrobial activity against Candida parapsilosis isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1301913 | Inhibition of hedgehog pathway in mouse ASZ cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by qPCR method | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. |
| AID572471 | Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369381 | Antimicrobial activity against Candida utilis isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID572462 | Half life in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564404 | Antimicrobial activity against Aspergillus fumigatus isolate 36 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID279053 | Cmax in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID555620 | Antimicrobial activity against Fusarium verticillioides by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID498146 | Antifungal activity against Candida tropicalis FMR 10333 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID567447 | Antifungal activity against Trichosporon sp. after 3 days by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID522547 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522552 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563354 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID432803 | Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro antifungal susceptibilities of five species of sporothrix. |
| AID1851973 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as inhibition of parasite growth incubated for 48 hrs by Hoechst 3348 staining based analysis | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID575201 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID524740 | Antimicrobial activity against Fusarium subglutinans after 48 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. |
| AID581871 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool receiving antifungal drug after 36 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564411 | Antimicrobial activity against Aspergillus fumigatus isolate 43 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID582232 | Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID369358 | Antimicrobial activity against Candida lusitaniae isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID283604 | Average plasma concentration in Candida albicans infected juvenile acute myelogenous leukemia patient with bone marrow transplantation at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID508574 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564190 | Antimicrobial activity against Aspergillus fumigatus isolate 31 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID516344 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as cell death at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID575362 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID508588 | Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein infected in CD1 mouse assessed as 50% effective pharmacodynamic index administered orally qd for 14 days measured post last dose | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID522466 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID575498 | Antifungal activity against Aspergillus lentulus isolate | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID522446 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID541894 | Toxicity in healthy human assessed as urine analysis at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID572685 | Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID530563 | Antimicrobial activity against Aspergillus fumigatus isolate AT infected in NMRI mouse assessed as survival rate at 5 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. |
| AID564176 | Antimicrobial activity against Aspergillus fumigatus isolate 17 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID730404 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as increase in host survival at 100 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infection mea | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID531236 | Antifungal activity against Candida parapsilosis after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID541873 | Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID575215 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID555797 | Antimicrobial activity against Alternaria alternata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID572666 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID519433 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4420 obtained from nail of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID575219 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1419553 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida glabrata ATCC 2001 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID521791 | Fungistatic activity against Candida glabrata isolate 4205 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID560469 | Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID1309046 | Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID522533 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID549329 | Antifungal activity against Apophysomyces spp. after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID525398 | Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID522538 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID598224 | Antimicrobial activity against Candida albicans isolate 47 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID555606 | Antimicrobial activity against Aspergillus niger by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID581882 | Antifungal activity against Candida glabrata isolated from HSCT recipient 975 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID572468 | Half life in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID582249 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1419499 | Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-1003 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID1898170 | Antifungal activity against Candida tropicalis ATCC750 | |||
| AID498166 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564511 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID322861 | Antifungal activity against azole-resistant Aspergillus fumigatus V41/26-CM3820 isolate from patient with pulmonary fibrosis by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID522483 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID519425 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3537 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID584417 | Antifungal activity against 12 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID322853 | Antifungal activity against azole-resistant Aspergillus fumigatus V13/02-CM3271 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID576446 | Cmin in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID575354 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID557631 | Fungicidal activity against Rhizopus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522535 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID582243 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID532351 | Antifungal activity against Bipolaris australiensis by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID582225 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD receiving posaconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID557626 | Fungicidal activity against amphotericin B-resistant Aspergillus terreus | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID532160 | Antifungal activity against Rhinocladiella aquaspersa | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID405092 | Antimicrobial activity against Rhizopus sp. after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID498010 | Antifungal activity against Candida tropicalis FMR 10236 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID1557091 | Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID498174 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID425171 | Antifungal activity against Candida glabrata isolate 4205 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID508328 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID575485 | Antifungal activity against azole-resistant Aspergillus fumigatus isolate R13 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 0.5 mg/l relative to control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID575497 | Antifungal activity against Aspergillus nidulans isolate | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID521796 | Fungistatic activity against Candida glabrata isolate 4205 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID555806 | Antimicrobial activity against Mycocladus corymbiferus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564606 | Antimicrobial activity against Aspergillus fumigatus isolate 29 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID598223 | Antimicrobial activity against Candida albicans isolate 41 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID572210 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID582999 | Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51B gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B. |
| AID673496 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 2 mg/kg, ip administered 8 days after post infection qd for 5 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID498178 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID508327 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564416 | Antimicrobial activity against Aspergillus fumigatus isolate 48 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID369352 | Antimicrobial activity against Candida tropicalis isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID532161 | Antifungal activity against Candida albicans by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555051 | Antimicrobial activity against Fusarium oxysporum FMR 10281 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID521789 | Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 25 mg/kg/day, ip administered 24 hrs po | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID508332 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564605 | Antimicrobial activity against Aspergillus fumigatus isolate 28 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1309050 | Antifungal activity against Candida albicans ATCC MYA-2310 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID369356 | Antimicrobial activity against Candida dubliniensis isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID521567 | Antifungal activity against Aspergillus fumigatus isolate AF 293 infected in ICR mouse assessed as decrease in (1-3)-beta-D-glucan concentration in serum at 40 mg/kg, po QD (RVb= 758 pg/ml) | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID278442 | Increase in survival of neutropenic CD1 mouse infected with 0.1 mega Rhizopus oryzae 4745 at 50 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID1534780 | Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID425373 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured at 15 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID555798 | Antimicrobial activity against Alternaria infectoria by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID283334 | Antifungal activity against Rhizomucor spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID531220 | Antimicrobial activity against Syncephalastrum racemosum hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID563357 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID567445 | Antifungal activity against Trichosporon mucoides assessed as percent susceptible isolates after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID584411 | Antifungal activity against 2 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522406 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID518611 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID541895 | Toxicity in healthy human assessed as vital adverse effects at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID541879 | Toxicity in healthy human plasma assessed as blood chemistry analysis at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID582998 | Antimicrobial activity against Saccharomyces cerevisiae YUG37 transformed with plasmid carrying cyp51A gene with doxycycline-regulatable promoter by broth dilution method in presence of doxycycline | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B. |
| AID564389 | Antimicrobial activity against Aspergillus fumigatus isolate 21 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID525412 | Fungistatic activity against Candida glabrata 4370 assessed as 99.9% reduction of int initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID1309055 | Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID564514 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID584416 | Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID557611 | Antifungal activity against Rhizomucor by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID369365 | Antimicrobial activity against Candida kefyr blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID532320 | Antifungal activity against Candida krusei by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564507 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID582227 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563406 | Antifungal activity against Aspergillus tubingensis isolate CM-4005 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID522441 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563389 | Antifungal activity against Aspergillus niger isolate CM-3506 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID279041 | Half life in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID532149 | Antifungal activity against Mucor species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575342 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID405105 | Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID369377 | Antimicrobial activity against Candida lusitaniae isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID564183 | Antimicrobial activity against Aspergillus fumigatus isolate 24 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID518402 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220R mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID546069 | Antifungal activity against Candida krusei isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID522560 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564026 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID283602 | Average plasma concentration in Fusarium spp infected juvenile osteosarcoma patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID531208 | Antimicrobial activity against Cunninghamella bertholletiae conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID405107 | Antimicrobial activity against Mucor sp. after assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID369370 | Antimicrobial activity against Candida glabrata isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID498142 | Antifungal activity against Candida tropicalis FMR 9726 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID559692 | Antimicrobial activity against Mycocladus corymbiferus after 24 hrs by broth microdilution checkerboard procedure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. |
| AID498015 | Antifungal activity against Candida tropicalis FMR 10241 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID575747 | Binding affinity to Aspergillus fumigatus AF293 sterol 14-alpha demethylase isoenzyme A expressed in Escherichia coli | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID541600 | Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID564667 | Antimicrobial activity against Aspergillus fumigatus isolate 40 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564400 | Antimicrobial activity against Aspergillus fumigatus isolate 32 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283598 | Average plasma concentration in Fusarium spp infected juvenile chronic myelogenous leukemia patient with bone marrow transplantation at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID557613 | Antifungal activity against Rhizopus by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522453 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID278453 | Reduction of infection foci size in Rhizopus oryzae 4570 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID425370 | Antifungal activity against Candida glabrata isolate 4293 at 5 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID525141 | Antifungal activity against Fusarium moniliforme clade 3 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. |
| AID584390 | Antifungal activity against 14 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID283328 | Antifungal activity against Absidia spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID283601 | Average plasma concentration in Aspergillus spp infected juvenile cystic fibrosis patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID541618 | Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID1534784 | Inhibition of human ERG expressed in CHO cells at 25 uM by electrophysiology assay relative to control | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID572463 | Half life in fasted healthy human at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564384 | Antimicrobial activity against Aspergillus fumigatus isolate 16 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522461 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID673487 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase of host survival at 10 mg/kg, po administered 8 days after post infection qd for 5 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID555573 | Antimicrobial activity against Candida kefyr by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID531212 | Antimicrobial activity against Absidia corymbifera conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID498161 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532128 | Antifungal activity against Candida krusei | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555604 | Antimicrobial activity against Aspergillus terreus by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID525598 | Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method relative to wildtype sCandida alb | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID555595 | Antimicrobial activity against Trichosporon jirovecii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555619 | Antimicrobial activity against Fusarium oxysporum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID555050 | Antimicrobial activity against Fusarium oxysporum FMR 5205 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID576259 | Ratio of fCmax in lung transplant recipient plasma after 12 hrs to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID279068 | Cmax in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID563418 | Antifungal activity against Aspergillus tubingensis isolate CM-4897 obtained from blood culture after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID555631 | Antimicrobial activity against Chrysonilia sitophila by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1898163 | Antifungal activity against Candida albicans 305 | |||
| AID283608 | Average plasma concentration in Coccidioides immitis infected juvenile at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID520619 | Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. |
| AID572208 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID531238 | Antifungal activity against Candida krusei after 48 hrs by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. |
| AID576460 | AUC (0 to 24 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID279195 | Antifungal activity against Aspergillus terreus conidia | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID547563 | Antifungal activity against Candida albicans after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID563345 | Antifungal activity against inoculum of 1x10'5 conidia/ml Fusarium solani isolate 95-2478 after 24 hrs by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID369387 | Antimicrobial activity against Candida inconspicua isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1557081 | Antifungal activity against Candida parapsilosis ATCC 90018 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID498353 | Cmax in patient undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID1898173 | Antifungal activity against Candida krusei 397 | |||
| AID1419547 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2310 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID575491 | Antifungal activity against azole-resistant Aspergillus fumigatus isolate T18 harboring Cyp51A TR/L98H mutation assessed as inhibition of fungal growth at 0.5 mg/l relative to control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID563378 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID555587 | Antimicrobial activity against Yarrowia lipolytica by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID522516 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID549322 | Antifungal activity against Rhizomucor variabilis after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID542725 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as mouse survival at 10 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID561907 | AUC (0 to infinity) in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID532133 | Antifungal activity against Cryptococcus neoformans var. neoformans | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID498183 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID563396 | Antifungal activity against Aspergillus niger isolate CM-4004 obtained from after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID564841 | Antimicrobial activity against Aspergillus fumigatus isolate 50 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID425165 | Antifungal activity against Candida glabrata isolate 4293 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID279198 | Antifungal activity against Aspergillus fumigatus hyphae | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID564375 | Antimicrobial activity against Aspergillus fumigatus isolate 7 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576482 | Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID258672 | Antifungal activity against Aspergillus species | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1 | Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. |
| AID1487214 | Inhibition of CYP51 in Aspergillus fumigatus assessed as inhibition of microbe growth incubated for 48 to 168 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID525400 | Antifungal activity against Candida glabrata isolate 4198 after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID541572 | Cmin in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID285216 | Mortality rate in Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID1309056 | Antifungal activity against Aspergillus flavus ATCC MYA-3631 after 48 hrs by CLSI M38-A2 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID575223 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID283597 | Average plasma concentration in Aspergillus spp infected juvenile burkitt's lymphoma patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID522449 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522469 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572416 | AUC in fasted healthy human at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID524016 | AUC (0 to 12 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID508582 | Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564621 | Antimicrobial activity against Aspergillus fumigatus isolate 44 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575069 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 40 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID559695 | Antimicrobial activity against Rhizomucor pusillus after 24 hrs by broth microdilution checkerboard procedure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. |
| AID521794 | Fungistatic activity against Candida glabrata 4370 assessed as 99.9% reduction of int initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID581863 | Antifungal activity against Candida albicans isolated from HSCT recipient 262 with acute or chronic GVHD mouth after 115 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID580585 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID279056 | Half life in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID563388 | Antifungal activity against Aspergillus niger isolate CM-3257 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID519444 | Antimicrobial activity against Neosartorya pseudofischeri isolate CNM-CM-3769 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID563346 | Antifungal activity against inoculum of 1x10'5 conidia/ml Fusarium solani isolate 95-2478 after 48 hrs by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID369159 | Antifungal activity against Snycephalastrum sp. strain 23 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID555809 | Antimicrobial activity against Cunninghamella bertholletiae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID369158 | Antifungal activity against Cunninghamella sp. strain 12 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID498148 | Antifungal activity against Candida tropicalis FMR 10235 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID522549 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID565401 | Antifungal activity against Rhizopus microsporus IHEM 9503 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID522414 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564439 | Antimicrobial activity against Aspergillus fumigatus isolate 21 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID394828 | Inhibition of human recombinant CYP3A4 | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6 | Rational modification of a candidate cancer drug for use against Chagas disease. |
| AID322852 | Antifungal activity against azole-resistant Aspergillus fumigatus M03/669-CM2627 isolate from patient by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID532335 | Antifungal activity against Absidia corymbifera by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1265814 | Antifungal activity against azole-resistant Candida albicans ATCC 10231 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID1595045 | Antifungal activity against Candida glabrata assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID561924 | AUC (0 to infinity) in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID498144 | Antifungal activity against Candida tropicalis FMR 10231 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564658 | Antimicrobial activity against Aspergillus fumigatus isolate 31 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283332 | Antifungal activity against Mucor spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID369160 | Antifungal activity against Rhizomucor sp. strain 25 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID564368 | Antimicrobial activity against Aspergillus fumigatus isolate 50 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564187 | Antimicrobial activity against Aspergillus fumigatus isolate 28 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563152 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID563399 | Antifungal activity against Aspergillus tubingensis isolate CM-4296 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID567435 | Antifungal activity against Trichosporon mucoides after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID598226 | Antimicrobial activity against Candida krusei isolate 31 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID369368 | Antimicrobial activity against Candida lusitaniae blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID581897 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx receiving antifungal drug after 21 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563369 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 12.5 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID572675 | Toxicity in healthy human assessed as headache at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575364 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID567428 | Antifungal activity against Dipodascus capitatus after 4 days by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID572447 | Apparent total body clearance in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID498152 | Antifungal activity against Candida tropicalis FMR 10239 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID572678 | Toxicity in healthy human assessed as asthenia at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572456 | Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564163 | Antimicrobial activity against Aspergillus fumigatus isolate 4 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID565563 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 40 mg/kg, po QD for 5 days measured after 24 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID555795 | Antimicrobial activity against Scedosporium apiospermum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID531468 | Antimicrobial activity against azole-susceptible Aspergillus fumigatus after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. |
| AID572220 | Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575360 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1419514 | Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID1587052 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 50 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and mea | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. |
| AID530558 | Antimicrobial activity against Aspergillus fumigatus isolate DK infected in NMRI mouse assessed as survival rate at 5 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. |
| AID516346 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as effect on cell division at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID1557090 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID498153 | Antifungal activity against Candida tropicalis FMR 10240 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID547569 | Antifungal activity against Candida guilliermondii after 24 to 72 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. |
| AID562118 | Tmax in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID581912 | Ratio of ERG11 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to ERG11 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID498138 | Antifungal activity against Candida tropicalis FMR 8895 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID524020 | AUC (0 to 24 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID564420 | Antimicrobial activity against Aspergillus fumigatus isolate 2 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575191 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID584401 | Antifungal activity against 60 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1860607 | Antitrypanosomal activity against Trypanosoma cruzi infected in Vero cells assessed as relapse day after washout at 25 times EC50 for 8 days followed by washout by microscopic analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease. |
| AID518595 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, F495I mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID555582 | Antimicrobial activity against Candida orthopsilosis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID560486 | Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID508585 | Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID541576 | Cmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID1851972 | Solubility of compound in water at 0.1 M HCl at pH 1 by LC-UV analysis | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID581879 | Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID546070 | Antifungal activity against Candida parapsilosis isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID279048 | Cmax in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID560481 | Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in kidney tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID564174 | Antimicrobial activity against Aspergillus fumigatus isolate 15 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564413 | Antimicrobial activity against Aspergillus fumigatus isolate 45 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283338 | Antifungal activity against Syncephalastrum spp after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID532137 | Antifungal activity against Geotrichum candidum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564370 | Antimicrobial activity against Aspergillus fumigatus isolate 2 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID508576 | Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID522480 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2447 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID581894 | Antifungal activity against Candida albicans isolated from HSCT recipient 928 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID405096 | Antimicrobial activity against Mucor sp. after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID581875 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1497 with AML or MDS pharynx receiving antifungal drug after 61 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563148 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID575205 | Antifungal activity against Cunninghamella echinulata UTHSC 03-3725 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1546310 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 20A trypomastigote expressing GFP infected in BALB/c mouse cardiomyocytes assessed as reduction in parasitemia measured after 72 hrs by fluorescence assay | 2020 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1 | A new chemotype with promise against Trypanosoma cruzi. |
| AID572457 | Half life in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369354 | Antimicrobial activity against Candida krusei isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID555592 | Antimicrobial activity against Trichosporon inkin by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564396 | Antimicrobial activity against Aspergillus fumigatus isolate 28 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576488 | Ratio of fAUC (0 to 12 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID516338 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as reduction in fecosterol content at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID555803 | Antimicrobial activity against Cladophialophora bantiana by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID533027 | Antifungal activity against Aspergillus fumigatus ATCC 9197 grown as biofilm on CFBE41o cell after 24 to 48 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. |
| AID564518 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID1419568 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida krusei ATCC 6258 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID405094 | Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID581878 | Antifungal activity against Candida glabrata isolated from HSCT recipient 186 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522492 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID576441 | Ratio of AUC (0 to 24 hrs) in lung transplant recipient alveolar cell to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID557811 | Drug level in patient serum with infection by HPLC analysis | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Posaconazole therapeutic drug monitoring: a reference laboratory experience. |
| AID584386 | Antifungal activity against 29 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS pharynx after 48 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID582248 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564654 | Antimicrobial activity against Aspergillus fumigatus isolate 27 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572422 | AUC in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564634 | Antimicrobial activity against Aspergillus fumigatus isolate 7 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576442 | AUC (0 to 24 hrs) in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID369151 | Toxicity in invasive zygomycosis diseased patient assessed as mortality | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID557618 | Antifungal activity against Aspergillus flavus hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID582237 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving posaconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID521570 | Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed as pulmonary fungal burden at 40 mg/kg, po QD | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID563372 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID572441 | Tmax in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522400 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID279062 | Apparent total clearance in >=65 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID567438 | Antifungal activity against Trichosporon inkin after 48 hrs by Etest | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. |
| AID581872 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1187 with AML or MDS stool after 22 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID555580 | Antimicrobial activity against Candida inconspicua by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID557624 | Antifungal activity against Cunninghamella hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID285219 | Effect on survival in Trypanosoma cruzi Y infected C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID575359 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in brain at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522399 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-278 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522558 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522545 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID584405 | Antifungal activity against 23 days cultured Candida glabrata isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID575213 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID563137 | Antifungal activity against Scedosporium boydii FMR 8627 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID580598 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID1474112 | Ratio of drug concentration at steady state in human at 200 mg, po TID after 8 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID425365 | Antifungal activity against Candida glabrata isolate 4370 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID565399 | Antifungal activity against Rhizopus microsporus IHEM 18821 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID576485 | Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID279074 | Tmax in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID584591 | Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID283333 | Antifungal activity against Mucor spp after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. |
| AID598227 | Antimicrobial activity against Candida krusei isolate 43 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID522531 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541575 | Cmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522436 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3827 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID525404 | Antifungal activity against Candida glabrata isolate 4293 after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID572676 | Toxicity in healthy human assessed as headache at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522506 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572671 | Toxicity in healthy human assessed as dizziness at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563347 | Drug concentration in uninfected nonimmunosppressed ICR mouse serum at 50 mg/kg, po BID after 4 hrs | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID671574 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as level of parasite in blood at 20 mg/kg, po qd for 20 days measured after 30 day | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID563371 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID522524 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522501 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1241 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522559 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1898171 | Antifungal activity against Candida krusei 463 | |||
| AID598229 | Antimicrobial activity against Candida tropicalis isolate 33 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID279045 | AUC (0-12 hrs) in >=65 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID572415 | AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1487225 | Inhibition of CYP19 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID581906 | Ratio of CDR1 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to CDR1 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522432 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID575488 | Antifungal activity against azole-susceptible Aspergillus fumigatus isolate CM-237 assessed as fungal growth at 0.5 mg/l relative to control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID532338 | Antifungal activity against Rhizopus oryzae by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1898164 | Antifungal activity against Candida albicans 20# | |||
| AID369374 | Antimicrobial activity against Candida krusei isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID598303 | Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 25 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID369155 | Antifungal activity against Absidia strain 11 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID521798 | Antifungal activity against 2.44 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 15 mg/kg/day, po administered 24 hrs po | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID522527 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID555626 | Antimicrobial activity against Phialemonium curvatum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID498147 | Antifungal activity against Candida tropicalis FMR 10234 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID518616 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54E mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID541606 | Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 24 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID498181 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 25 mg/kg, po bid for 5 dayss | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532146 | Antifungal activity against Rhizopus oryzae | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575350 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID522460 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1684563 | Antifungal activity against Aspergillus flavus ATCC 3631 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID509113 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID541587 | Tmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID405111 | Antimicrobial activity against Absidia corymbifera assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID322864 | Antifungal activity against azole-resistant Aspergillus fumigatus V49/09-CM4023 isolate from patient with chronic obstructive pulmonary disease by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID575073 | Antifungal activity against Cunninghamella bertholletiae FMR 9598 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1301912 | Inhibition of hedgehog pathway in mouse C3H10T1/2 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by qPCR method | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. |
| AID564604 | Antimicrobial activity against Aspergillus fumigatus isolate 27 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563821 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID522526 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425366 | Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.015 ug/ml caspofungin measured at 0.5 ug/ml after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID584589 | Antifungal activity against 15 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID498355 | Apparent volume of distribution in patient undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID584599 | Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1265840 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H- | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID1557089 | Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID283607 | Average plasma concentration in Scedosporium apiospermum infected juvenile chronic myelogenous leukemia patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID581876 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1491 with AML or MDS pharynx after 23 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID322859 | Antifungal activity against azole-resistant Aspergillus fumigatus V34/77-CM3278 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID532126 | Antifungal activity against Candida glabrata | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522424 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-3110 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425382 | Antifungal activity against 2.44 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as reduction in colony forming units treated with a therapeutic regimen of sterile saline solution from day 1 to day 2 followed by 15 mg/kg/day drug a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID509108 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in lung compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID564835 | Antimicrobial activity against Aspergillus fumigatus isolate 44 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1171004 | Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as reduction in fecosterol level at 100 nM incubated for 24 hrs by GC-MS method | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. |
| AID1265819 | Antifungal activity against azole-resistant Candida albicans MYA-1237 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID522499 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID519448 | Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-3147 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID497999 | Antifungal activity against Candida tropicalis FMR 8895 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID572216 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID580597 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID278437 | Increase in survival of Rhizopus oryzae 4570 infected neutropenic CD1 mouse at 20 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID522557 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564193 | Antimicrobial activity against Aspergillus fumigatus isolate 34 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572217 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576490 | Protein binding in human plasma at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID532337 | Antifungal activity against Rhizopus microsporus var. oligosporus by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID524019 | AUC (0 to 12 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID572658 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID508577 | Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID575482 | Antifungal activity against azole-resistant Aspergillus fumigatus isolate T11 harboring Cyp51A TR/L98H mutant gene assessed as inhibition of fungal growth at 0.5 mg/l relative to control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID572430 | Tmax in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage and proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1595051 | Antifungal activity against Candida albicans V-01-191A-261 assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID1689827 | Antifungal activity against Mucor circinelloides MURI1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID580578 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID541592 | Ratio of Cmax in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID1383456 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.05 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID522507 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID524736 | Antimicrobial activity against Fusarium verticillioides after 48 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. |
| AID557623 | Antifungal activity against Mucor hyphae by EUCAST method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID572667 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1898176 | Antifungal activity against Candida auris 791 | |||
| AID564394 | Antimicrobial activity against Aspergillus fumigatus isolate 26 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID531214 | Antimicrobial activity against Rhizomucor spp. hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID584593 | Antifungal activity against 56 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID572473 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576471 | Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID518594 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S297T, F495 mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID1487215 | Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID560462 | Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID572680 | Toxicity in healthy human assessed as asthenia at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID508333 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564388 | Antimicrobial activity against Aspergillus fumigatus isolate 20 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID508323 | Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID532150 | Antifungal activity against Cunninghamella species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID532350 | Antifungal activity against Curvularia lunata by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID375462 | Terminal half life in rat | 2009 | Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12 | Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. |
| AID541614 | Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522563 | Drug level in human serum at 400 mg, po bid | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498001 | Antifungal activity against Candida tropicalis FMR 8897 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID522554 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564391 | Antimicrobial activity against Aspergillus fumigatus isolate 23 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID532336 | Antifungal activity against Absidia species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID525591 | Antibacterial activity against Fluconazole resistant Candida albicans DSY296 overexpressing multidrug transporter gene CDR1 and CDR2 and containing ERG11 G464S mutation by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID564608 | Antimicrobial activity against Aspergillus fumigatus isolate 31 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1557079 | Antifungal activity against Candida glabrata ATCC 2001 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID279040 | AUC (0-12 hrs) in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID509106 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in kidney compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID575357 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID549312 | Antifungal activity against Mucor circinelloides after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID522555 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564626 | Antimicrobial activity against Aspergillus fumigatus isolate 49 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575214 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID509399 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 20 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID532324 | Antifungal activity against Saccharomyces cerevisiae by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID498004 | Antifungal activity against Candida tropicalis FMR 9727 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID565562 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus UTHSC 01-983 at 20 mg/kg, po BID for 5 days measured after 24 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1301915 | Antiproliferative activity against mouse MERP MB cells assessed as cell growth inhibition using methyl-[3H]thymidine after 48 hrs by liquid scintillation spectrophotometry | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. |
| AID572668 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID584394 | Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx after 12 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID322854 | Antifungal activity against azole-resistant Aspergillus fumigatus V13/03-CM3272 isolate from patient with X-linked chronic granulomatous disease by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID1294729 | Antileishmanial activity against beta-lactamase expressing Leishmania amazonensis amastigotes overnight infected in CD1 mouse macrophages incubated for 72 hrs by nitrocefin dye based assay | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents. |
| AID508318 | AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID522482 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564624 | Antimicrobial activity against Aspergillus fumigatus isolate 47 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID279066 | Half life in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID516323 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as abnormalities in nuclear membrane at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID519443 | Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-4328 obtained from cornea of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID532127 | Antifungal activity against Candida parapsilosis | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564188 | Antimicrobial activity against Aspergillus fumigatus isolate 29 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID498354 | Apparent oral clearance in patient undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID531227 | Antimicrobial activity against Absidia corymbifera hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID572413 | AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532158 | Antifungal activity against Curvularia lunata | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID279057 | Apparent total clearance in 18-45 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID781109 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in 3T3 cells after 7 days by beta-galactosidase assay | 2013 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23 | Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents. |
| AID1534787 | Inhibition of hedgehog signaling pathway in hedgehog-dependent mouse Ptch-CKO cells assessed as inhibition of cell growth | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID563358 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID580667 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID1265844 | Antifungal activity against azole-resistant Candida albicans ATCC 64124 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID1689828 | Antifungal activity against Fusarium sp. assessed as reduction in microbial growth after 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID581902 | Antifungal activity against Candida glabrata isolated from HSCT recipient 807 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID545662 | Cellular uptake in PBMC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID557812 | Drug level in patient serum with invasive aspergillosis by HPLC analysis | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Posaconazole therapeutic drug monitoring: a reference laboratory experience. |
| AID563809 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID432796 | Antifungal activity against Candida kefyr ATCC 46764 at 1.5 ug/ml after 14 to 18 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. |
| AID576470 | Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID575345 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID541594 | Ratio of AUC (0 to 24 hrs) in healthy human plasma at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID581904 | Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564415 | Antimicrobial activity against Aspergillus fumigatus isolate 47 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID519423 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3134 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID541612 | Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522429 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1301 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522405 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1613 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID561910 | Cmax in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564510 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID283596 | Average plasma concentration in ITT population of adult patients with Aspergillus infection at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID572660 | Toxicity in healthy human assessed as adverse events at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563404 | Antifungal activity against Aspergillus tubingensis isolate CM-3810 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID572659 | Toxicity in healthy human assessed as adverse events at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575070 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID564028 | Antifungal activity against Fusarium oxysporum isolate infected in ICR mouse | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID509112 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID283605 | Average plasma concentration in Candida albicans infected juvenile with inherited immunodeficiency at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID425167 | Antifungal activity against Candida glabrata isolate 4370 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID576484 | Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1474111 | Drug concentration at steady state in human at 200 mg, po TID after 8 hrs | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID508313 | Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID561908 | AUC (0 to infinity) in healthy human at 400 mg/kg, po by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID561915 | Terminal half life in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID582255 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID525602 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3606 containing tac1delta/delta ERG11-1/ERG11-1 (TAC1-5) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID575218 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1309049 | Antifungal activity against Candida albicans ATCC MYA-90819 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID283606 | Average plasma concentration in Aspergillus spp infected juvenile acute lymphoblastic leukemia patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID522433 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-2374 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID369395 | Antimicrobial activity against Trichosporon loubieri isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID564641 | Antimicrobial activity against Aspergillus fumigatus isolate 14 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID279051 | Half life in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID1062780 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 10 mg/kg, po qd administered on day 8 post-infection for 20 days measured on day 28 post-infection by microscopic analysis | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID575372 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID581908 | Ratio of ERG11 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to ERG11 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1184055 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigotes expressing green florescent protein infected in cardiomyocytes assessed as inhibition of parasite growth after 72 hrs by fluorescence microscopy | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition. |
| AID1684564 | Antifungal activity against Fusarium falciforme ATCC 3636 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID508580 | Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID519442 | Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3740 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID581900 | Antifungal activity against Candida glabrata isolated from HSCT recipient 497 with acute or chronic GVHD mouth after 114 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID560487 | Antifungal activity against Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID560456 | Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID572419 | AUC in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564645 | Antimicrobial activity against Aspergillus fumigatus isolate 18 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID405093 | Antimicrobial activity against Rhizopus arrhizus after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID575352 | Antifungal activity against Cunninghamella bertholletiae FMR-9598 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID559694 | Antimicrobial activity against Rhizopus microsporus after 24 hrs by broth microdilution checkerboard procedure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. |
| AID564623 | Antimicrobial activity against Aspergillus fumigatus isolate 46 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564203 | Antimicrobial activity against Aspergillus fumigatus isolate 44 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID518604 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID278450 | Reduction of number of infection foci in Absidia corymbifera 4535 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID564655 | Antimicrobial activity against Aspergillus fumigatus isolate 28 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID598222 | Antimicrobial activity against Candida albicans isolate 31 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID521566 | Antifungal activity against Aspergillus fumigatus isolate CEA 10 infected in ICR mouse assessed as decrease in (1-3)-beta-D-glucan concentration in serum at 40 mg/kg, po QD (RVb= 707 pg/ml) | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. |
| AID1419543 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2876 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID524007 | Tmax in high fat fed healthy human plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID564430 | Antimicrobial activity against Aspergillus fumigatus isolate 12 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576439 | Tmax in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID509102 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 20 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID564612 | Antimicrobial activity against Aspergillus fumigatus isolate 35 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522551 | Antifungal activity against drug-intermediate Rhizopus oryzae infected in OF1 mouse assessed as mouse survival at 30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522487 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3111 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541602 | Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID563825 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID283594 | Average plasma concentration in ITT population of adult patients with invasive fungal infection at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID283595 | Average plasma concentration in ITT population of juvenile patients with Aspergillus infection at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID545165 | Antimicrobial activity against Candida albicans isolate C after 48 hrs by EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID564613 | Antimicrobial activity against Aspergillus fumigatus isolate 36 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572482 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID509400 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 40 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID532327 | Antifungal activity against Trichosporon inkin by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555630 | Antimicrobial activity against Hormographiella verticillata by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID1484686 | Leishmanicidal activity against Leishmania panamensis LS94 promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID541877 | T>MIC90 in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID730419 | Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID1595049 | Antifungal activity against Candida tropicalis assessed as reduction in fungal cell growth incubated for 48 hrs by broth microdilution method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170 | Tetrazole hybrids and their antifungal activities. |
| AID564407 | Antimicrobial activity against Aspergillus fumigatus isolate 39 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID532345 | Antifungal activity against Penicillium marneffei by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID565075 | Antimicrobial activity against Blastoschizomyces capitatus by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. |
| AID1689826 | Antifungal activity against Rhizopus oryzae RHPOR2 assessed as reduction in microbial growth after 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID531217 | Antimicrobial activity against Rhizopus oryzae hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID519435 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4428 obtained from skin of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID572431 | Tmax in fasted healthy human at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID580666 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivation of infection at 20 mg/kg/day, po administered once daily for 20 consecutive days measured 22 days post infe | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID519430 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4370 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID584395 | Antifungal activity against 8 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID561917 | Tmax in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564194 | Antimicrobial activity against Aspergillus fumigatus isolate 35 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID559693 | Antimicrobial activity against Mucor circinelloides after 24 hrs by broth microdilution checkerboard procedure | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. |
| AID584592 | Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID545330 | Antimicrobial activity against Candida albicans isolate C after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID1534781 | Half life in human liver microsomes at 1 uM by LC-MS/MS analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID576494 | AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID369382 | Antimicrobial activity against Candida lipolytica isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID1851971 | Solubility of compound in water at pH 7 by LC-UV analysis | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID572426 | AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID279060 | AUC (0-12 hrs) in >=65 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID369383 | Antimicrobial activity against Candida pelliculosa isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID564024 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID522410 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID541599 | Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID541603 | Drug level in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID531229 | Antimicrobial activity against Rhizomucor spp. hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID541593 | Ratio of Cmax in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID576477 | Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID541591 | Ratio of Cmax in healthy human plasma at 400 mg, po every 12 hrs for 7 days to MIC90 for Aspergillus spp. | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID278471 | Percentage of infected spleen in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID563390 | Antifungal activity against Aspergillus tubingensis isolate CM-3507 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID508316 | AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 4 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID575220 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 40 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID279063 | Cmax in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID369366 | Antimicrobial activity against Candida dubliniensis blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID498011 | Antifungal activity against Candida tropicalis FMR 10237 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID575363 | Antifungal activity against Cunninghamella bertholletiae UTSCH 05-2275 infected in diabetic OF1 mouse assessed as decreased fungal load in lung at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID564172 | Antimicrobial activity against Aspergillus fumigatus isolate 13 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1898168 | Antifungal activity against Candida parapsilosis 700 | |||
| AID572214 | Cmax in healthy human plasma at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369393 | Antimicrobial activity against Candida rugosa isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID565560 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 20 mg/kg, po BID for 5 days measured after 3 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID532332 | Antifungal activity against Aspergillus flavus by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555609 | Antimicrobial activity against Aspergillus versicolor by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID564196 | Antimicrobial activity against Aspergillus fumigatus isolate 37 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID518598 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, N125I mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID516329 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as blebbing of the cell membrane at 0.25 uM after 48 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID563360 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID546076 | Antifungal activity against Candida rugosa isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID508578 | Cmax in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID1419571 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus nidulans ATCC 38163 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID498140 | Antifungal activity against Candida tropicalis FMR 8897 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID584402 | Antifungal activity against 88 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 75 days after 33 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID576473 | Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 24 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID532151 | Antifungal activity against Scedosporium prolificans | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564185 | Antimicrobial activity against Aspergillus fumigatus isolate 26 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID518405 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220K mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID582234 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID278433 | Antimicrobial activity against Rhizopus oryzae 4570 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID1706435 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis relative to | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID563138 | Antifungal activity against Scedosporium boydii FMR 6694 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID563375 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID498356 | Apparent oral clearance in patient without diarrhea undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID1534785 | Substrate activity at P-gp in human Caco2 cells by LC-MS/MS analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID541613 | Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID375461 | Terminal half life in mouse | 2009 | Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12 | Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. |
| AID572418 | AUC in fasted healthy human at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572476 | Apparent volume of distribution in fasted healthy human at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID555566 | Antimicrobial activity against Candida albicans by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID572682 | Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID509104 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 10 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID524023 | AUC (0 to 24 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID555588 | Antimicrobial activity against Galactomyces geotrichum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID549324 | Antifungal activity against Cunninghamella spp. after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID564635 | Antimicrobial activity against Aspergillus fumigatus isolate 8 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572455 | Apparent total body clearance in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532153 | Antifungal activity against Penicillium marneffei | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1309057 | Antifungal activity against Aspergillus nidulans ATCC 38163 after 48 hrs by CLSI M38-A2 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID278440 | Increase in survival of Absidia corymbifera 4535 infected neutropenic CD1 mouse at 80 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID1689825 | Antifungal activity against Rhizopus oryzae RHPOR1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID584414 | Antifungal activity against 16 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1419565 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida albicans ATCC 10231 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID522484 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4336 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID279071 | Half life in white racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID532157 | Antifungal activity against Sporothrix schenckii | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1487224 | Inhibition of CYP17 hydroxylase in human hepatocyte microsomes using pregnenolone substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID283603 | Average plasma concentration in Candida krusei infected juvenile acute lymphoblastic leukemia patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID564377 | Antimicrobial activity against Aspergillus fumigatus isolate 9 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1309054 | Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID531230 | Antimicrobial activity against Mucor spp. hyphae after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID1587053 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 25 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and mea | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. |
| AID564659 | Antimicrobial activity against Aspergillus fumigatus isolate 32 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575343 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID541573 | Cmin in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID560463 | Antifungal activity against 5 x 10'7 CFU Candida krusei FMR9729 infected OF1 mouse disseminated infection model assessed as prolongation of mouse survival at 100 mg/kg/day, po for 5 days administered 24 hrs postinfection measured daily for 15 days | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID1171003 | Inhibition of sterol biosynthesis in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells assessed as reduction in episterol level at 100 nM incubated for 24 hrs by GC-MS method | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. |
| AID521790 | Fungistatic activity against Candida glabrata isolate 4198 assessed as 99.9% reduction of initial fungal load at 0.5 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID564648 | Antimicrobial activity against Aspergillus fumigatus isolate 21 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID565552 | Antifungal activity against Rhizopus microsporus UTHSC R-3466 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID541897 | Half life in human | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID532331 | Antifungal activity against Aspergillus terreus by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID598300 | Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 14 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID1557094 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID575198 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in diabetic OF1 mouse assessed as increase in mouse survival rate at 60 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1309048 | Antifungal activity against Candida albicans ATCC MYA-2876 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID564609 | Antimicrobial activity against Aspergillus fumigatus isolate 32 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575344 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID563417 | Antifungal activity against Aspergillus tubingensis isolate CM-4352 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID278455 | Reduction of infection foci size in Rhizopus oryzae 4570 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID572684 | Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID498180 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532352 | Antifungal activity against Rhinocladiella aquaspersa by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1265815 | Antifungal activity against azole-resistant Candida albicans ATCC 64124 after 48 hrs by microbroth dilution method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID564382 | Antimicrobial activity against Aspergillus fumigatus isolate 14 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564435 | Antimicrobial activity against Aspergillus fumigatus isolate 17 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564436 | Antimicrobial activity against Aspergillus fumigatus isolate 18 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID541609 | Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 8 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID564425 | Antimicrobial activity against Aspergillus fumigatus isolate 7 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID498008 | Antifungal activity against Candida tropicalis FMR 10234 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532346 | Antifungal activity against Penicillium species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID560474 | Antifungal activity against Candida krusei FMR9728 infected OF1 mouse disseminated infection model assessed as reduction in spleen tissue fungal burden at 50 mg/kg/day, po for 5 days administered 24 hrs postinfection measured after 24 hrs post treatment r | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Efficacy of triazoles in a murine disseminated infection by Candida krusei. |
| AID572218 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564646 | Antimicrobial activity against Aspergillus fumigatus isolate 19 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID545665 | Drug uptake in plasma of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID598302 | Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 30 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID572221 | Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID1419548 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against ITC and FLC-susceptible Candida albicans ATCC MYA-2310 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564840 | Antimicrobial activity against Aspergillus fumigatus isolate 49 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584595 | Antifungal activity against 176 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 172 days after 114 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522510 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563355 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID532134 | Antifungal activity against Cryptococcus neoformans var. gattii | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID519427 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3583 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID673468 | Plasma concentration in Swiss mouse at 20 mg/kg, po after 24 hrs | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID1498545 | Inhibition of Candida albicans CYP51 assessed as reduction in [3-3H]lanosterol 14alpha-demethylation at 0.75 uM preincubated for 60 secs followed by NADPH addition measured after 60 mins by RP-HPLC analysis relative to control | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID1419567 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Candida krusei ATCC 6258 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID518596 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, S52T mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID582226 | Antifungal activity against Candida krusei isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID561909 | AUClast in healthy human at 400 mg/kg administered via nasogastric tube by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564636 | Antimicrobial activity against Aspergillus fumigatus isolate 9 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1547544 | Trypanosomacidal activity against Trypanosoma cruzi strain Y trypomastigotes assessed as reduction in number of infected cells at slower rate at 0.04 uM measured for 24 to 96 hrs by Hoechst 33342 staining based fluorescence imaging assay | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Discovery of Potent |
| AID285221 | Effect on survival in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID582239 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID563407 | Antifungal activity against Aspergillus tubingensis isolate CM-4688 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID425379 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of amphotericin B MIC measured at 15 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID581886 | Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1265843 | Antifungal activity against azole-resistant Candida albicans ATCC 10231 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID1498550 | Potency index, ratio of VNI Kd(app) to compound Kd(app) for Candida albicans CYP51 | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID279047 | Apparent total clearance in >=65 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID576258 | fAUC (0 to 12 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID498013 | Antifungal activity against Candida tropicalis FMR 10239 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID369162 | Antifungal activity against Mucor strain 39 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID405102 | Antimicrobial activity against Apophysomyces elegans after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID519434 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4426 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID518608 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, M172V, L358L, E427K, C454C mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID565398 | Antifungal activity against Rhizopus microsporus CBS 102277 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID581909 | Ratio of URA3 gene expression in Candida glabrata isolated from patient 186 receiving antifungal drug to URA3 gene expression in Candida glabrata isolated from patient 186 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID498154 | Antifungal activity against Candida tropicalis FMR 10241 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID522423 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID531211 | Antimicrobial activity against Rhizopus microsporus conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID564422 | Antimicrobial activity against Aspergillus fumigatus isolate 4 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID259824 | Antiprotozoal activity against Trypanosoma cruzi epimastigotes | 2006 | Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3 | Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. |
| AID1062804 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 20 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment measured on day 37 post-infection by mi | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID521788 | Antifungal activity against 2.44 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 25 mg/kg/day, ip administered 24 hrs po | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID532044 | Antifungal activity against Lichtheimia corymbifera clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID563802 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID546081 | Antifungal activity against Candida intermedia isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID498176 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID575200 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID561913 | Apparent oral clearance in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID522420 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-197 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563419 | Antifungal activity against Aspergillus tubingensis isolate CM-4899 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID555621 | Antimicrobial activity against Paecilomyces variotii by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID584413 | Antifungal activity against 9 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID561921 | Elimination rate in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID524015 | Cmin in high fat fed healthy human skin at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID557629 | Fungicidal activity against Rhizomucor | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID532156 | Antifungal activity against Fusarium oxysporum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID575341 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID532138 | Antifungal activity against Aspergillus fumigatus | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID555804 | Antimicrobial activity against Scytalidium hyalinum by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. |
| AID258671 | Antifungal activity against Candida albicans | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1 | Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. |
| AID563798 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID516342 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cell assessed as abnormalities in nuclear membrane at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID524014 | Cmin in high fat fed healthy human plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID532042 | Antifungal activity against Lichtheimia ramosa clinical isolate after 48 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID563411 | Antifungal activity against Aspergillus niger isolate CM-3551 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID564652 | Antimicrobial activity against Aspergillus fumigatus isolate 25 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID541615 | Ratio of Drug level in healthy human alveolar cell to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID572469 | Half life in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572438 | Tmax in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576486 | Drug level in lung transplant recipient plasma at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID584398 | Antifungal activity against 14 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool after 12 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID730408 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI infected in Swiss mouse model of Chagas disease assessed as decrease in blood parasitemia level at 50 mg/kg once daily for 5 consecutive days through oral gavage starting on day 8 post infe | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. |
| AID575068 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as increase in mouse survival rate at 20 mg/kg, po qd administered 1 day after infection for 7 days relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID518400 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A G54W mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID425363 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID563420 | Antifungal activity against Aspergillus foetidus isolate CM-4995 obtained from prosthesis after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID522418 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-3132 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID549319 | Antifungal activity against Rhizopus microsporus after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID564376 | Antimicrobial activity against Aspergillus fumigatus isolate 8 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522417 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4035 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572683 | Toxicity in healthy human assessed as nausea at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522521 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1062795 | Plasma concentration in Swiss mouse at 20 mg/kg, po after 24 hrs by LC/MS analysis | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID524022 | AUC (0 to 24 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID1383454 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as residual activity at 0.005 uM by fluorescence based analysis (Rvb = 100%) | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID522401 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-2882 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID405099 | Antimicrobial activity against Rhizomucor sp. after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID518404 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A M220V mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID549311 | Antifungal activity against Rhizopus oryzae after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID575202 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID519422 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-1290 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID522561 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as reduction in kidney fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564204 | Antimicrobial activity against Aspergillus fumigatus isolate 45 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID522470 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 02-439 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564195 | Antimicrobial activity against Aspergillus fumigatus isolate 36 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572219 | Cmax in healthy human plasma at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID425369 | Antifungal activity against Candida glabrata isolate 4293 assessed as viable yeast cells pretreated overnight with 0.25 ug/ml caspofungin measured at 4 ug/ml measured after 48 hrs | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID572448 | Apparent total body clearance in fasted healthy human at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522459 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID524024 | T>MIC90 in fungus infected patient plasma at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID565403 | Antifungal activity against Rhizopus microsporus IHEM 4770 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1898165 | Antifungal activity against Candida albicans 28# | |||
| AID565565 | Antifungal activity against Rhizopus microsporus FMR 3542 infected in OF1 mouse assessed as reduction in fungal load in brain at 40 mg/kg, QD for 5 days | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1301914 | Antiproliferative activity against HUVEC assessed as inhibition of VEGF induced cell proliferation after 72 hrs by MTS assay | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. |
| AID581899 | Antifungal activity against Candida glabrata isolated from HSCT recipient 002 with acute or chronic GVHD mouth receiving antifungal drug after 116 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID549314 | Antifungal activity against Mycocladus corymbifer after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID549313 | Antifungal activity against Mucor circinelloides after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID1294748 | Antileishmanial activity against Leishmania amazonensis infected in mouse J774 cells after 72 hrs using 2 hrs parasite exposed mouse J774 cells | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents. |
| AID564668 | Antimicrobial activity against Aspergillus fumigatus isolate 41 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563413 | Antifungal activity against Aspergillus tubingensis isolate CM-4000 after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID576475 | Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522488 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1679 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498156 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532043 | Antifungal activity against Lichtheimia corymbifera clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID564644 | Antimicrobial activity against Aspergillus fumigatus isolate 17 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572414 | AUC in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572669 | Toxicity in healthy human assessed as dizziness at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369364 | Antimicrobial activity against Candida krusei blood isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID575226 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID572207 | Cmax in fasted healthy human plasma at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID405100 | Antimicrobial activity against Absidia corymbifera after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID572417 | AUC in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576449 | Ratio of AUC (0 to 24 hrs) in lung transplant recipient epithelial lining fluid to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID546079 | Antifungal activity against Candida lipolytica isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID581896 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1331 with AML or MDS pharynx after 21 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID575349 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID564414 | Antimicrobial activity against Aspergillus fumigatus isolate 46 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID508581 | Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID563822 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID581884 | Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth after 108 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1419503 | Antifungal activity against Aspergillus flavus ATCC MYA-3631 incubated for 48 hrs by CLSI M38-A2 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID498151 | Antifungal activity against Candida tropicalis FMR 10238 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564666 | Antimicrobial activity against Aspergillus fumigatus isolate 39 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1487222 | Inhibition of CYP11B2 in human hepatocyte microsomes using deoxycorticosteroid substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID279073 | Cmax in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID369375 | Antimicrobial activity against Candida dubliniensis isolate from superficial infection | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID564385 | Antimicrobial activity against Aspergillus fumigatus isolate 17 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID565554 | Antifungal activity against Rhizopus microsporus UTHSC 04-3294 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1419572 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Aspergillus nidulans ATCC 38163 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID673470 | Plasma concentration in Swiss mouse at 50 mg/kg, po after 8 hrs | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID532333 | Antifungal activity against Aspergillus niger by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID542722 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 10 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID576492 | Cmax in healthy human epithelial lining fluid at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID425161 | Antifungal activity against Candida glabrata isolate 4198 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID522512 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-1826 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID508321 | Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 16 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564205 | Antimicrobial activity against Aspergillus fumigatus isolate 46 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID369154 | Antifungal activity against Rhizopus strain 8 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID522498 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4133 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563348 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID564670 | Antimicrobial activity against Aspergillus fumigatus isolate 43 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584409 | Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID405112 | Antimicrobial activity against Cunninghamella sp. assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID509101 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in OF1 mouse assessed as increase in mouse survival at 40 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID580668 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID278449 | Reduction of number of infection foci in Absidia corymbifera 4535 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID425362 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID532132 | Antifungal activity against Saccharomyces cerevisiae | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID576438 | Ratio of Cmax in lung transplant recipient alveolar cell after 12 hrs to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID522508 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1080 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID582224 | Antifungal activity against Candida glabrata isolated from HSCT recipients with acute or chronic GVHD prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID575206 | Antifungal activity against Cunninghamella echinulata FMR 10974 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID519426 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3538 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID522465 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-1351 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID575217 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1265848 | Antifungal activity against azole-resistant Candida albicans MYA-1237 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)- | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID522530 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522542 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-114 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498141 | Antifungal activity against Candida tropicalis FMR 8898 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID508586 | Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID279052 | Apparent total clearance in 18-45 yr old man plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID498172 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID519432 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-4415 obtained from sputum of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID1498548 | Binding affinity to Candida albicans CYP51 by spectral titration method | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID541898 | Protein binding in human | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID278434 | Antimicrobial activity against Rhizopus oryzae 4745 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID564522 | Antifungal activity against Scedosporium aurantiacum IHEM 15458 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID1265836 | Antifungal activity against azole-resistant Candida albicans ATCC 10231 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H-pyran | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID532152 | Antifungal activity against Scedosporium apiospermum | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID532347 | Antifungal activity against Fusarium solani by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID522425 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-2970 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID532323 | Antifungal activity against Candida guilliermondii by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID598301 | Antimicrobial activity against Cryptococcus neoformans var. neoformans isolate 27 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID542723 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic BALB/c mouse assessed as improved time to death at 30 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID572686 | Toxicity in healthy human assessed as fatigue at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532330 | Antifungal activity against Aspergillus fumigatus by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID565557 | Drug level in serum of OF1 mouse infected with Rhizopus microsporus FMR 3542 at 40 mg/kg, po QD measured after 3 hrs post last dose | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID564199 | Antimicrobial activity against Aspergillus fumigatus isolate 40 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575224 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 0.8 mg/kg, iv qd administered 1 day post infection measured after 4 to 5 days relative to untreated con | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1419540 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida albicans ATCC 64124 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID1419504 | Antifungal activity against Aspergillus nidulans ATCC 38163 incubated for 48 hrs by CLSI M38-A2 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID1557086 | Antifungal activity against Candida albicans SN152 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID564657 | Antimicrobial activity against Aspergillus fumigatus isolate 30 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID498143 | Antifungal activity against Candida tropicalis FMR 9727 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID576476 | Drug level in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 5 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID516336 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cells assessed as accumulation of lanosterol and eburicol precursors at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID524021 | AUC (0 to 24 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID508584 | Antifungal activity against wild type Aspergillus fumigatus infected in CD1 mouse assessed as increase in mouse survival rate administered orally qd for 14 days measured on day 15 post fungal infection | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID522462 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-2975 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID522404 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-89 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID576454 | T>MIC90 for Aspergillus spp. infected lung transplant recipient plasma at 400 mg, po every 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID283593 | Average plasma concentration in ITT population of juvenile patients with invasive fungal infection at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID524017 | AUC (0 to 12 hrs) in high fat fed healthy human plasma measured per ml of plasma at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID1487218 | Inhibition of CYP51 in Aspergillus flavus assessed as inhibition of microbe growth incubated for 48 to 168 hrs by CLSI M27-A3 guideline based method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID564387 | Antimicrobial activity against Aspergillus fumigatus isolate 19 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID549316 | Antifungal activity against Cunninghamella bertholletiae after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID572467 | Half life in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID508312 | Antifungal activity against Aspergillus fumigatus isolate V28-77 harboring M220I mutation in Cyp51A protein by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID405098 | Antimicrobial activity against Mucor circinelloides after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID584410 | Antifungal activity against -3 days cultured Candida tropicalis isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 45 days after 24 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564437 | Antimicrobial activity against Aspergillus fumigatus isolate 19 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID584588 | Antifungal activity against -2 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID580579 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as mean survival time at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID425782 | Antifungal activity against Candida parapsilosis PA/71 grown as planktonic cell assessed as minimum drug level required to decrease turbidity by 50% after 24 hrs by CLSI M27-A2 method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID531223 | Antimicrobial activity against Rhizomucor spp. conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID563810 | Antifungal activity against Scedosporium boydii FMR 6694 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID522491 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564663 | Antimicrobial activity against Aspergillus fumigatus isolate 36 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID581890 | Antifungal activity against Candida albicans isolated from HSCT recipient 462 with acute or chronic GVHD mouth after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID581870 | Antifungal activity against Candida glabrata isolated from neutropenic subject 1318 with AML or MDS stool after 36 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID519436 | Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-4063 obtained from bronchoalveolar aspirate of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID576462 | AUC (0 to 12 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID545152 | Antimicrobial activity against Candida albicans isolate R after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID1684562 | Antifungal activity against Aspergillus fumigatus ATCC 3626 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID516327 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as appearance of large autophagic vesicles at 0.25 uM after 48 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID673461 | Kinetic solubility of the compound at pH 6.5 by nephelometric analysis | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID369380 | Antimicrobial activity against Saccharomyces cerevisiae isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID563373 | Antifungal activity against mid- inoculum 6.5 x 10'5 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 12.5 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID508589 | Antifungal activity against Aspergillus fumigatus isolate V52-35 harboring TR L98H mutation in Cyp51A protein infected in CD1 mouse assessed as 50% effective pharmacodynamic index administered orally qd for 14 days measured post last dose | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID572674 | Toxicity in healthy human assessed as headache at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572212 | Cmax in healthy human plasma at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522539 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID584389 | Antifungal activity against 1 day cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID572687 | Toxicity in healthy human assessed as dizziness at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID561919 | Cmax in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID522472 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-511 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1265847 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2310 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiom | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID1419554 | Selectivity index, ratio of EC50 for toxicity in human BEAS2B cells to MIC50 for antifungal activity against Candida glabrata ATCC 2001 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID549320 | Antifungal activity against Rhizomucor pusillus after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID575347 | Antifungal activity against Cunninghamella bertholletiae UTHSC 04-2581 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID564519 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in brain fungal burden at 40 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID522481 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-1220 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522562 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 05-3032 infected in OF1 mouse assessed as reduction in brain fungal load at 10-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID498163 | Antifungal activity against Candida tropicalis FMR 10237 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID557810 | Drug level in patient serum with acute graft-versus-host disease by HPLC analysis | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Posaconazole therapeutic drug monitoring: a reference laboratory experience. |
| AID581905 | Antifungal activity against Candida glabrata isolated from HSCT recipient 491 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID546075 | Antifungal activity against Candida guilliermondii isolated from candidemia patient by AFST-EUCAST microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. |
| AID565404 | Antifungal activity against Rhizopus microsporus IHEM 5234 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID582252 | Antifungal activity against Candida albicans isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1684559 | Antifungal activity against Mucor ramosissimus ATCC 90286 | 2021 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 33 | Highly potent, broadly active antifungal agents for the treatment of invasive fungal infections. |
| AID576461 | Ratio of AUC (0 to 12 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID532321 | Antifungal activity against Candida lusitaniae by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID525600 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3604 containing tac1delta/delta ERG11-1/ERG11-5 genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID509103 | Antifungal activity against 2 x 10'5 CFU Fonsecaea monophora CBS 117236 infected in OF1 mouse assessed as increase in mouse survival at 40 mg/kg, po qd administered 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID279042 | Apparent total clearance in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID564618 | Antimicrobial activity against Aspergillus fumigatus isolate 41 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID285217 | Mortality rate in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID278458 | Reduction of infection foci size in Absidia corymbifera 4535 infected neutropenic CD1 mouse brain at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID531209 | Antimicrobial activity against Mucor spp. conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID425374 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.125 times of caspofungin MIC measured at 5 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID522398 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID561923 | AUClast in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID581860 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID1557083 | Antifungal activity against Candida guilliermondii T-47 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID285218 | Mortality rate in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model at 20 mg/kg, po twice daily after 20 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. |
| AID525590 | Antibacterial activity against azole-susceptible Candida albicans DSY294 by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID532322 | Antifungal activity against Candida tropicalis by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID561912 | Cmax in healthy human at 400 mg/kg, po by ITT analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID564630 | Antimicrobial activity against Aspergillus fumigatus isolate 3 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID581910 | Ratio of CDR1 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to CDR1 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID531216 | Antimicrobial activity against Mucor spp. hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID563817 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID576491 | Cmax in healthy human plasma at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID532045 | Antifungal activity against Lichtheimia ornata clinical isolate after 24 hrs by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. |
| AID572434 | Tmax in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID498003 | Antifungal activity against Candida tropicalis FMR 9726 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID541607 | Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 3 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID532139 | Antifungal activity against Aspergillus terreus | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID518600 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, A284A mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID519438 | Antimicrobial activity against Aspergillus fumisynnematus isolate CNM-CM-3227 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID519424 | Antimicrobial activity against Aspergillus lentulus isolate CNM-CM-3364 obtained from bronchoalveolar lavage fluid of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID673466 | Plasma concentration in Swiss mouse at 20 mg/kg, po after 1 hr | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID563797 | Antifungal activity against Scedosporium apiospermum IHEM 14464 infected in immunosuppressed OF1 mouse assessed as prolonged survival of mouse at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID521970 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3752 containing (TAC1-5/TAC1-5 ERG11-1/ERG11-1) genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID576464 | Ratio of drug level in lung transplant human recipient alveolar cell to plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID278445 | Reduction of number of infection foci in Rhizopus oryzae 4570 infected neutropenic CD1 mouse kidney at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID525599 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method sCandida albicans DSY294 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID563140 | Antifungal activity against Scedosporium apiospermum IHEM 14464 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID564650 | Antimicrobial activity against Aspergillus fumigatus isolate 23 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572432 | Tmax in healthy human at 400 mg BID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564429 | Antimicrobial activity against Aspergillus fumigatus isolate 11 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID516328 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as swelling of nuclear membrane at 0.25 uM after 48 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID279067 | Apparent total clearance in >=65 yr old woman plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID405104 | Antimicrobial activity against Rhizopus arrhizus assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID564399 | Antimicrobial activity against Aspergillus fumigatus isolate 31 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564191 | Antimicrobial activity against Aspergillus fumigatus isolate 32 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575208 | Antifungal activity against Cunninghamella echinulata UTHSC 01-2298 after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID565550 | Antifungal activity against Rhizopus microsporus IHEM 13311 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID1419494 | Antifungal activity against Candida albicans ATCC 64124 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID598232 | Antimicrobial activity against Candida tropicalis isolate 22 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID541571 | Cmin in healthy human plasma at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID572213 | Cmax in fasted healthy human plasma at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532339 | Antifungal activity against Rhizopus species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564421 | Antimicrobial activity against Aspergillus fumigatus isolate 3 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572655 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576450 | Cmax in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID541874 | Ratio of Drug level in healthy human lung epithelial lining fluid to drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID522475 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1817 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID563379 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 50 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID405095 | Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID522402 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522419 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-547 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID524009 | Tmax in high fat fed healthy human skin at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID572480 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522541 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 04-3109 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID425169 | Antifungal activity against Candida glabrata isolate 4198 pretreated overnight with 0.5 times of caspofungin MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID1309052 | Antifungal activity against Candida albicans ATCC MYA-1003 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID532141 | Antifungal activity against Aspergillus niger | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID1419549 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC 1237 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID564627 | Antimicrobial activity against Aspergillus fumigatus isolate 50 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1546308 | Binding affinity to full length Trypanosoma cruzi Tulahuen C4 C-terminal His-tagged CYP51 expressed in Escherichia coli HMS174 (DE3) assessed as induction of shift in Soret band by spectrophotometry | 2020 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1 | A new chemotype with promise against Trypanosoma cruzi. |
| AID572656 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension coadministered with acidic carbonated beverage | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID563813 | Antifungal activity against Scedosporium boydii FMR 8627 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 10 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID564610 | Antimicrobial activity against Aspergillus fumigatus isolate 33 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564653 | Antimicrobial activity against Aspergillus fumigatus isolate 26 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID581881 | Antifungal activity against Candida glabrata isolated from HSCT recipient 474 with acute or chronic GVHD mouth receiving antifungal drug after 124 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID425786 | Antifungal activity against Candida albicans M61 grown as biofilm assessed as 50% reduction in metabolic activity of biofilm at 64 mg/liter after 24 hrs by XTT assay | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. |
| AID425376 | Antifungal activity against Candida glabrata isolate 4293 pretreated overnight with 0.5 times of amphotericin B MIC measured at 5 ug/disk after 24 hrs by halo assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID498150 | Antifungal activity against Candida tropicalis FMR 10237 assessed as compound concentration causing =>99% reduction in microbial growth | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID563818 | Antifungal activity against Scedosporium apiospermum CBS 117407 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID576261 | Cmin in lung transplant recipient alveolar cell at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID498359 | Apparent volume of distribution in patient with diarrhea undergoing allogenic hematopoietic stem cell transplantation | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. |
| AID1851975 | Cytotoxicity against mouse 3T3 cells | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID519449 | Antimicrobial activity against Aspergillus viridinutans isolate CNM-CM-4518 obtained from nail of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID572478 | Apparent volume of distribution in fasted healthy human at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572461 | Half life in fasted healthy human at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID549318 | Antifungal activity against Rhizopus microsporus after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID524737 | Antimicrobial activity against Fusarium solani after 48 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. |
| AID532136 | Antifungal activity against Trichosporon asahii | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID584597 | Antifungal activity against 1 day cultured Candida krusei isolated from neutropenic subject with AML or MDS pharynx receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID572437 | Tmax in fasted healthy human at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID541880 | Toxicity in healthy human plasma assessed as hematological analysis at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID564372 | Antimicrobial activity against Aspergillus fumigatus isolate 4 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1309047 | Antifungal activity against Candida albicans ATCC 64124 after 48 hrs by CLSI M27-A3 method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. |
| AID576469 | Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID541598 | Drug level in healthy human plasma at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID1498546 | Inhibition of Aspergillus fumigatus CYP51 assessed as reduction in [3-3H]eburicol 14alpha-demethylation at 0.75 uM preincubated for 60 secs followed by NADPH addition measured after 60 mins by RP-HPLC analysis relative to control | 2018 | Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13 | Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic |
| AID541590 | AUC (0 to 12 hrs) in healthy human alveolar cell at 400 mg, po every 12 hrs for 7 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID576257 | fAUC (0 to 24 hrs) in lung transplant recipient plasma at 400 mg, po every 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID581862 | Antifungal activity against Candida krusei isolated from neutropenic subjects with AML or MDS receiving fluconazole assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564433 | Antimicrobial activity against Aspergillus fumigatus isolate 15 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575751 | Antimicrobial activity against sterol 14-alpha demethylase isoenzyme B-deficient Aspergillus fumigatus CEA10 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID598296 | Antimicrobial activity against Candida parapsilosis isolate 26 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID572421 | AUC in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564182 | Antimicrobial activity against Aspergillus fumigatus isolate 23 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563376 | Antifungal activity against low - inoculum 7.5 x 10'4 conidia/ml Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated 2 days prior of infection | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID555276 | Antimicrobial activity against 1X 10'7 CFU Fusarium oxysporum FMR 5205 infected in immunosuppressed-OF1 mouse assessed as reduction in spleen fungal burden at 100 mg/kg, po administered 1 day post infection measured on day 6 post dosing | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. |
| AID369394 | Antimicrobial activity against Pichia ohmeri isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID498160 | Antifungal activity against Candida tropicalis FMR 8895 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 25 mg/kg, po bid for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564412 | Antimicrobial activity against Aspergillus fumigatus isolate 44 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575499 | Antifungal activity against Aspergillus fumigatus isolates harboring Cyp51A TR/L98H mutation by EUCAST method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID1706434 | Cytotoxicity against rat 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID1689829 | Antifungal activity against Scedosporium apiospermum SCAP1 assessed as reduction in microbial growth after 24 hrs by broth microdilution method | 2020 | European journal of medicinal chemistry, Mar-01, Volume: 189 | New azole antifungals with a fused triazinone scaffold. |
| AID1419515 | Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID576489 | Ratio of fAUC (0 to 24 hrs) in lung transplant recipient plasma to MIC90 for Aspergillus spp. | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID1265849 | Antifungal activity against azole-resistant Candida albicans MYA-1003 assessed as fractional inhibition after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)- | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID522415 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522496 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564647 | Antimicrobial activity against Aspergillus fumigatus isolate 20 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID542729 | Antifungal activity against Rhizopus oryzae 99-880 infected in diabetic ketoacidotic mouse assessed as reduction of fungal burden in brain at 60 mg/kg/day, po administered 8 hrs post infection for 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID279196 | Antifungal activity against Aspergillus flavus conidia | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID521797 | Fungistatic activity against Candida glabrata isolate 4293 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID522476 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID572436 | Tmax in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564184 | Antimicrobial activity against Aspergillus fumigatus isolate 25 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID582236 | Antifungal activity against Candida glabrata isolated from neutropenic subjects with AML or MDS prior to initiation of posaconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID564639 | Antimicrobial activity against Aspergillus fumigatus isolate 12 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID525592 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3083 containing tac1delta/delta genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID516334 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as reduction in episterol content at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID522428 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-434 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522513 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564169 | Antimicrobial activity against Aspergillus fumigatus isolate 10 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID535617 | Antifungal activity against Candida tropicalis T7 blood stream isolate | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. |
| AID598295 | Antimicrobial activity against Candida glabrata isolate 49 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID498012 | Antifungal activity against Candida tropicalis FMR 10238 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID565553 | Antifungal activity against Rhizopus microsporus UTHSC 03-1802 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. |
| AID278435 | Antimicrobial activity against Absidia corymbifera 4535 | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID581887 | Antifungal activity against Saccharomyces cerevisiae isolated from HSCT recipient 513 with acute or chronic GVHD mouth receiving antifungal drug after 112 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID549328 | Antifungal activity against Apophysomyces spp. after 24 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID564427 | Antimicrobial activity against Aspergillus fumigatus isolate 9 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564661 | Antimicrobial activity against Aspergillus fumigatus isolate 34 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1171000 | Volume of distribution in human | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. |
| AID584590 | Antifungal activity against 43 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 168 days after 113 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID521795 | Fungistatic activity against Candida glabrata isolate 4198 assessed as 99.9% reduction of initial fungal load at 8 times MIC after 48 hrs using colony count method by time-kill method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID509098 | Antifungal activity against Fonsecaea monophora CBS 269.37 | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID547621 | Cytotoxicity against BESM cells after 88 hrs by HTS assay | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. |
| AID522489 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 07-365 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID542732 | Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic mouse assessed as reduction of fungal burden in brain at 60 mg/kg/day, po administered 8 hrs post infection for 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID522546 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-51 infected in OF1 mouse assessed as increase in mouse survival at 20-30 mg/kg, po bid treated 24 hrs after fungal infection | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID322863 | Antifungal activity against azole-resistant Aspergillus fumigatus V48/27-CM3936 isolate from patient with acute myeloid leukemia by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID1419569 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against Aspergillus flavus ATCC MYA-3631 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID532344 | Antifungal activity against Scedosporium apiospermum by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID584598 | Antifungal activity against 6 days cultured Candida krusei isolated from neutropenic subject with AML or MDS stool receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID531470 | Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring M220V, M220K, M220T and M220I mutation in cyp51A gene after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. |
| AID1873196 | Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by liquid scintillation counter analysis | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. |
| AID522504 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID405113 | Antimicrobial activity against Apophysomyces elegans assessed as percent of susceptible isolates after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. |
| AID572661 | Toxicity in healthy human assessed as adverse events at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564607 | Antimicrobial activity against Aspergillus fumigatus isolate 30 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563826 | Antifungal activity against Scedosporium aurantiacum CBS 116910 infected in immunosuppressed OF1 mouse assessed as reduction in kidney fungal burden at 20 mg/kg, po BID administered 24 hrs postinfection for 10 days measured after 20 days | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Experimental murine scedosporiosis: histopathology and azole treatment. |
| AID564398 | Antimicrobial activity against Aspergillus fumigatus isolate 30 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564637 | Antimicrobial activity against Aspergillus fumigatus isolate 10 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID425158 | Antifungal activity against Candida glabrata isolate 4198 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID564198 | Antimicrobial activity against Aspergillus fumigatus isolate 39 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID575227 | Antifungal activity against Cunninghamella bertholletiae UTHSC 03-2241 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID508326 | Apparent oral clearance in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID572425 | AUC in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 10 mg metoclopramide | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID369385 | Antimicrobial activity against Geotrichum capitatum isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID580596 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID519450 | Antimicrobial activity against Aspergillus fumigatus ATCC 2004305 after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID522457 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2159 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID584369 | Ratio of URA3 gene expression in Candida glabrata isolated from patient 975 receiving antifungal drug to URA3 gene expression in Candida glabrata isolated from patient 975 by RT-PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID598292 | Antimicrobial activity against Candida glabrata isolate 30 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID572673 | Toxicity in healthy human assessed as headache at 400 mg BID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564386 | Antimicrobial activity against Aspergillus fumigatus isolate 18 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572451 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension 5 mins before consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID564162 | Antimicrobial activity against Aspergillus fumigatus isolate 3 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID531221 | Antimicrobial activity against Absidia corymbifera conidia after 24 hrs by AFST-EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID1706437 | Selectivity index, ratio of IC50 for cytotoxicity against rat 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. |
| AID524018 | AUC (0 to 12 hrs) in high fat fed healthy human skin measured per gram of tissue at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID575216 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in brain at 80 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contr | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID508579 | Tmax in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID283599 | Average plasma concentration in Aspergillus fumigatus infected juvenile chronic granulomatous disease patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID564200 | Antimicrobial activity against Aspergillus fumigatus isolate 41 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID572433 | Tmax in fasted healthy human at 200 mg QID, po administered as suspension for 7 days | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID525402 | Antifungal activity against Candida glabrata isolate 4205 after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID598294 | Antimicrobial activity against Candida glabrata isolate 46 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID518603 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing wild type cyp51A gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID563400 | Antifungal activity against Aspergillus niger isolate CM-4316 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID564170 | Antimicrobial activity against Aspergillus fumigatus isolate 11 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID562117 | Cmax in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID1419496 | Antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-90819 incubated for 48 hrs by modified CLSI M27-A3 protocol based method | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID1062802 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 amastigotes infected in rat L6 cells after 96 hrs by colorimetric method | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24 | Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. |
| AID522490 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522500 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-443 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564171 | Antimicrobial activity against Aspergillus fumigatus isolate 12 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID549323 | Antifungal activity against Rhizomucor variabilis after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. |
| AID498171 | Antifungal activity against Candida tropicalis FMR 9726 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse spleen at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID524006 | Tmax in high fat fed healthy human plasma at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID522509 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-4152 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID575752 | Antimicrobial activity against Aspergillus fumigatus CEA10 | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. |
| AID522495 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-228 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID525594 | Antibacterial activity against Fluconazole resistant Candida albicans DSY3706 containing tac1delta/delta ERG11-1/ERG11-1 genotype by EUCAST standards based broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. |
| AID522412 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-329 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID531213 | Antimicrobial activity against Syncephalastrum racemosum conidia after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID564602 | Antimicrobial activity against Aspergillus fumigatus isolate 25 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID564165 | Antimicrobial activity against Aspergillus fumigatus isolate 6 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576472 | Ratio of drug level in lung transplant human recipient epithelial lining fluid to plasma at 400 mg, po every 12 hrs after 3 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID369157 | Antifungal activity against Absidia strain 18 zygomycota by conventional morphological method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. |
| AID509398 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse brain at 10 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID541608 | Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 5 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID498169 | Antifungal activity against Candida tropicalis FMR 10239 infected in immunosuppressed OF1 mouse assessed as reduction in fungal tissue burden in mouse kidney at 50 mg/kg, po qd for 5 dayss | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532147 | Antifungal activity against Rhizopus species | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID563409 | Antifungal activity against Aspergillus tubingensis isolate CM-3125 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID673495 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 10 mg/kg, ip administered 8 days after post infection qd for 5 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID545664 | Cellular uptake in RBC of patient with hematological malignancies at 200 mg/kg administered 3 to 4 times a day measured by liquid chromatography-tandem mass spectroscopy | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Intracellular concentrations of posaconazole in different compartments of peripheral blood. |
| AID564836 | Antimicrobial activity against Aspergillus fumigatus isolate 45 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID322855 | Antifungal activity against azole-resistant Aspergillus fumigatus V27/28-CM3273 isolate from patient by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID576493 | Cmax in healthy human alveolar cell at 400 mg, po BID by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID572449 | Apparent total body clearance in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID576480 | Drug level in lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs after 8 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID584419 | Antifungal activity against 85 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 143 days after 116 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID584406 | Antifungal activity against 25 days cultured Candida glabrata isolated from invasive fungal infected subject blood receiving antifungal therapy for 25 days after 3 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID522409 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 2868 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID522440 | Antifungal activity against drug-intermediate Rhizopus oryzae UTHSC 03-285 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID432802 | Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | In vitro antifungal susceptibilities of five species of sporothrix. |
| AID581885 | Antifungal activity against Candida glabrata isolated from HSCT recipient 270 with acute or chronic GVHD mouth receiving antifungal drug after 108 days prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID516333 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi epimastigotes infected in BESM cells assessed as accumulation of lanosterol and eburicol precursors at 5 uM after 72 hrs | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID576457 | Tmax in lung transplant recipient plasma at 400 mg, po every 12 hrs after 12 hrs by LC/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID524008 | Tmax in high fat fed healthy human skin at 400 mg, po bid after 1 day | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID498157 | Antifungal activity against Candida tropicalis FMR 9727 infected in immunosuppressed OF1 mouse assessed as prolongation of mouse survival at 50 mg/kg, po qd for 5 days | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID564402 | Antimicrobial activity against Aspergillus fumigatus isolate 34 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID542731 | Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic mouse assessed as reduction of fungal burden in kidneys at 60 mg/kg/day, po administered 8 hrs post infection for 3 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID575221 | Antifungal activity against Cunninghamella bertholletiae UTHSC 06-1945 infected in neutropenic OF1 mouse assessed as decreased fungal load in kidney at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated cont | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID279046 | AUC (0-12 hrs) in >=65 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID425170 | Antifungal activity against Candida glabrata isolate 4205 pretreated overnight with 0.5 times of amphotericin B MIC measured after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID522437 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-299 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID1898160 | Antifungal activity against Candida albicans 25# | |||
| AID529668 | Antimicrobial activity against Paecilomyces lilacinus by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Susceptibility testing and molecular classification of Paecilomyces spp. |
| AID1383443 | Inhibition of recombinant Trypanosoma cruzi Tulahuen CYP51 expressed in Escherichia coli JM109 cell membranes assessed as inhibition of microbe growth by fluorescence based analysis | 2018 | European journal of medicinal chemistry, Apr-10, Volume: 149 | Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. |
| AID572464 | Half life in healthy human at 200 mg QID, po administered as suspension for 7 days coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID531218 | Antimicrobial activity against Rhizopus microsporus hyphae after 24 hrs by XTT method in presence of amphotericin B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. |
| AID564180 | Antimicrobial activity against Aspergillus fumigatus isolate 21 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID598306 | Antimicrobial activity against Candida parapsilosis ATCC 22019 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID542730 | Antifungal activity against Rhizopus oryzae 99-880 infected in neutropenic BALB/c mouse assessed as improved time to death at 60 mg/kg/day, po administered 24 hrs post infection for 4 days | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis. |
| AID580586 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID1851974 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as reduction in parasite growth at Emax concentration incubated for 48 hrs by Hoechst 3348 staining based analysis | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID564629 | Antimicrobial activity against Aspergillus fumigatus isolate 2 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID563397 | Antifungal activity against Aspergillus niger isolate CM-4213 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID509105 | Antifungal activity against 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected in po dosed OF1 mouse assessed as reduction in fungal load in spleen compound administered qd 1 day after infection for 7 days | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID541610 | Drug level in healthy human lung epithelial lining fluid at 400 mg, po every 12 hrs for 7 days measured after 12 hrs of last dose | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. |
| AID1898225 | Cytotoxicity against HUVEC assessed as cell viability at 64 ug/ml incubated for 24 hrs by CCK-8 assay | |||
| AID1898172 | Antifungal activity against Candida krusei 629 | |||
| AID1557087 | Antifungal activity against Candida glabrata ATCC 66032 assessed as reduction in fungal cell growth incubated for 48 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID1898179 | Antifungal activity against Candida auris D12 | |||
| AID563578 | Cmin in healthy human plasma before initiation of 6 mg/kg BID | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. |
| AID1487223 | Inhibition of CYP17 lyase in human hepatocyte microsomes using 17a-hydroxypregnenolone substrate by HPLC/MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15 | Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. |
| AID564642 | Antimicrobial activity against Aspergillus fumigatus isolate 15 by oxygen consumption method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1265838 | Antifungal activity against azole-susceptible Candida albicans ATCC MYA-2876 after 48 hrs in presence of (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-((1R,2S,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6S)-4-amino-6-(dodecylthiomethyl)-3,5-dihydroxytetrahydro-2H- | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles. |
| AID522505 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-731 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID279077 | Apparent total clearance in black racial/ethnic human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID524028 | Toxicity in healthy human assessed as treatment-emergent adverse events at 400 mg, po bid after 8 days | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Skin concentrations and pharmacokinetics of posaconazole after oral administration. |
| AID278475 | Percentage of infected kidney in neutropenic CD1 mouse infected with Absidia corymbifera 4535 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID519441 | Antimicrobial activity against Neosartorya hiratsukae isolate CNM-CM-3764 obtained from oropharyngeal exudate of patient after 48 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. |
| AID522532 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 03-112 after 24 to 48 hrs | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID564175 | Antimicrobial activity against Aspergillus fumigatus isolate 16 by CLSI M38-A2 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID563362 | Antifungal activity against high inoculum 2.9 x 10'6 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID580590 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID508330 | Plasma concentration in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured at 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID564410 | Antimicrobial activity against Aspergillus fumigatus isolate 42 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID283600 | Average plasma concentration in Candida spp infected juvenile acute myelogenous leukemia patient at 800 mg/day, po | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. |
| AID572654 | Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement and 4 mg loperamide as two 2 mg tablets | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572453 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID518610 | Antimicrobial activity against itraconazole-susceptible Aspergillus fumigatus clinical isolate expressing cyp51A F46Y, G89G, M172V, N248T, D255E, E427K mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID584602 | Antifungal activity against 19 days cultured Candida krusei isolated from invasive fungal infected subject blood receiving antifungal therapy for 19 days after 6 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID508315 | AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 1 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID532334 | Antifungal activity against Rhizomucor species by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID516321 | Inhibition of sterol 14-alpha-demethylase in Trypanosoma cruzi amastigotes infected in BESM cell assessed as cell death at 0.25 uM after 72 hrs by electron microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. |
| AID582240 | Antifungal activity against Candida albicans isolated from HSCT recipients with acute or chronic GVHD prior to initiation of fluconazole therapy assessed as maximum MIC by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID545166 | Antimicrobial activity against Candida albicans isolate C after 48 hrs by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| AID522464 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 05-1502 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID531471 | Antimicrobial activity against azole-resistant Aspergillus fumigatus harboring Tandem repeat-L98H (TR) mutation in cyp51A gene after 48 hrs by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. |
| AID521799 | Antifungal activity against 1.04 x 10'8 CFU fluconazole-susceptible Candida glabrata isolate 4293 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs po | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID572444 | Apparent total body clearance in fasted healthy human at 400 mg administered as single dose suspension coadministered with proton pump inhibitor | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID673500 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 20 mg/kg, po administered after 2 cycles of immunosuppression qd for 10 days | 2012 | Journal of medicinal chemistry, May-10, Volume: 55, Issue:9 | Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. |
| AID572664 | Toxicity in healthy human assessed as adverse events at 400 mg administered as single dose suspension after 20 mins after consumption of high fat meal | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID279194 | Antifungal activity against Aspergillus fumigatus conidia | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. |
| AID584392 | Antifungal activity against 19 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth after 17 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID580592 | Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. |
| AID584415 | Antifungal activity against 31 days cultured Candida glabrata isolated from HSCT recipient with acute or chronic GVHD mouth receiving antifungal therapy for 31 days after 28 days of prophylaxis by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. |
| AID497819 | Antifungal activity against Fusarium sp. clinical isolates after 48 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro activity of thimerosal against ocular pathogenic fungi. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID572420 | AUC in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID575496 | Antifungal activity against Aspergillus niger isolate | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. |
| AID1599287 | Antiviral activity against DENV2 16881 infected in African green monkey Vero cells by qRT-PCR analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Recent update on anti-dengue drug discovery. |
| AID522427 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 412-546 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID369396 | Antimicrobial activity against Trichosporon mucoides isolate | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. |
| AID572472 | Apparent volume of distribution in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID532328 | Antifungal activity against Trichosporon asahii by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564434 | Antimicrobial activity against Aspergillus fumigatus isolate 16 after 48 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1484682 | Leishmanicidal activity against Leishmania amazonensis JOSEPHA promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID563367 | Antifungal activity against inoculum range 6.5 x 10'5 to 6.8 x 10'5 conidia/animal Fusarium solani infected in ICR mouse assessed as bacterial count in kidney tissue at 50 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID561914 | Elimination rate in healthy human at 400 mg/kg administered via nasogastric tube | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. |
| AID521800 | Antifungal activity against fluconazole-susceptible Candida glabrata isolate 4205 infected neutropenic CD1 mouse disseminated candidiasis model assessed as reduction in kidney tissue fungal burden at 30 mg/kg/day, po administered 24 hrs post infection mea | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. |
| AID522455 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 04-2459 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID518601 | Antimicrobial activity against itraconazole-resistant Aspergillus fumigatus clinical isolate expressing cyp51A L98H, L339L mutant gene by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. |
| AID498009 | Antifungal activity against Candida tropicalis FMR 10235 assessed as inhibition of growth by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. |
| AID532326 | Antifungal activity against Cryptococcus neoformans var. gattii by EUCAST method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID564409 | Antimicrobial activity against Aspergillus fumigatus isolate 41 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID576445 | T>MIC90 for Aspergillus spp. infected lung transplant recipient epithelial lining fluid at 400 mg, po every 12 hrs by LS/MS analysis | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. |
| AID598305 | Antimicrobial activity against Candida krusei ATCC 6258 after 48 hrs by microdilution broth method | 2011 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11 | Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives. |
| AID1484681 | Leishmanicidal activity against Leishmania donovani 1S MHOM/SD/00/1S-2D promastigote forms after 18 hrs by indirect microscopic analysis | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. |
| AID532143 | Antifungal activity against Absidia corymbifera | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. |
| AID279039 | Tmax in 18-45 yr old human plasma at 400 mg, po twice daily after 8 days | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. |
| AID572222 | AUC in fasted healthy human at 400 mg administered as single dose suspension | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID572484 | Apparent volume of distribution in healthy human at 400 mg administered as single dose suspension coadministered with nutritional supplement | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. |
| AID522447 | Antifungal activity against drug-susceptible Rhizopus oryzae UTHSC 06-3913 at 5 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. |
| AID322860 | Antifungal activity against azole-resistant Aspergillus fumigatus V34/78-CM3279 isolate from patient with hyper-immunoglobulin E syndrome by broth microdilution susceptibility test | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. |
| AID509393 | Drug level in 1 x 10'6 CFU Fonsecaea monophora CBS 269.37 infected OF1 mouse serum at 10 mg/kg, po qd administered 1 day after infection measured on day 6 after 4 hrs of last treatment | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. |
| AID563356 | Antifungal activity against inoculum range 7.7 x 10'4 to 7.8 x 10'4 conidia/animal Fusarium solani infected in ICR mouse assessed as rate of survival at 6.25 mg/kg, po BID treated after 12 hrs of inoculation | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. |
| AID508322 | Dose normalised AUC in CD1 mouse infected with wild type Aspergillus fumigatus at 64 mg/kg, po qd for 14 days measured after 24 hrs post last dose by HPLC analysis | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. |
| AID1851976 | Selectivity index, ratio of CC50 for cytotoxicity against mouse 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. |
| AID564418 | Antimicrobial activity against Aspergillus fumigatus isolate 50 after 24 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. |
| AID1419545 | Selectivity index, ratio of EC50 for toxicity in human A549 cells to MIC50 for antifungal activity against ITC and FLC-resistant Candida albicans ATCC MYA-90819 | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Novel alkylated azoles as potent antifungals. |
| AID278461 | Percentage of infected brain in neutropenic CD1 mouse infected with Rhizopus oryzae 4570 at 30 mg/kg/day, po | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | Posaconazole prophylaxis in experimental systemic zygomycosis. |
| AID1557076 | Antifungal activity against Candida albicans P-87 assessed as reduction in fungal cell growth incubated for 24 hrs by MTT based broth double dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. |
| AID1534779 | Inhibition of hedgehog signaling pathway in mouse ASZ cells assessed as decrease in Gli1 mRNA expression after 48 hrs by qRT-PCR analysis | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. |
| AID425383 | Antifungal activity against 1.04 x 10'8 CFU Candida glabrata isolate 4293 infected in CD1 mouse assessed as reduction in colony forming units treated with a therapeutic regimen of sterile saline solution from day 1 to day 2 followed by 30 mg/kg/day drug a | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| AID563408 | Antifungal activity against Aspergillus foetidus isolate CM-5264 obtained from respiratory tract infection of patient after 48 hrs by EUCAST broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. |
| AID575212 | Antifungal activity against Cunninghamella bertholletiae UTHSC 05-2275 infected in neutropenic OF1 mouse assessed as decreased fungal load in lung at 60 mg/kg, po qd administered 1 day post infection measured after 4 to 5 days relative to untreated contro | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (1.62) | 18.2507 |
| 2000's | 395 (25.67) | 29.6817 |
| 2010's | 902 (58.61) | 24.3611 |
| 2020's | 217 (14.10) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (77.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 103 (6.54%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 178 (11.30%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 350 (22.22%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 37 (2.35%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 907 (57.59%) | 84.16% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections [NCT03336502] | Phase 1 | 70 participants (Actual) | Interventional | 2017-12-20 | Completed | ||
| Pharmacokinetic of Intravenous Posaconazole in Critically Ill Patients [NCT05275179] | 10 participants (Actual) | Observational | 2021-02-11 | Completed | |||
| A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis [NCT00423267] | Phase 3 | 16 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potentia [NCT03796533] | 120 participants (Anticipated) | Interventional | 2018-12-10 | Recruiting | |||
| A Phase 0 Clinical Trial of Two Candidate Azoles (Ketoconazole and Posaconazole) for Patients With Recurrent High Grade Glioma [NCT03763396] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2019-08-01 | Active, not recruiting | ||
| Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) [NCT01377480] | Phase 2 | 120 participants (Actual) | Interventional | 2011-07-06 | Completed | ||
| Pharmacokinetics of Posaconazole Given as a Single Intravenous Dose to Obese Subjects: Dosing Obese With Noxafil® Under a Trial (DONUT) [NCT03246386] | Phase 4 | 24 participants (Actual) | Interventional | 2017-11-05 | Completed | ||
| An Open-label, Randomized, 2-period, 2-sequence Study to Evaluate the Single-dose Pharmacokinetics of Milademetan When Administered Alone or Concomitantly With Itraconazole or Posaconazole in Healthy Subjects [NCT03614455] | Early Phase 1 | 36 participants (Actual) | Interventional | 2018-07-13 | Completed | ||
| A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies [NCT04771130] | Phase 1/Phase 2 | 260 participants (Anticipated) | Interventional | 2021-05-24 | Recruiting | ||
| A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (T [NCT04368559] | Phase 3 | 462 participants (Anticipated) | Interventional | 2020-05-11 | Recruiting | ||
| Prospective Validation and Clinical Evaluation of a New Posaconazole Dosing Regimen for Children and Adolescents With Cystic Fibrosis and Aspergillus Infection [NCT04966234] | Phase 2/Phase 3 | 135 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral F901318 (Combined With Fluconazole and Posaconazole) in AML [NCT03036046] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn(stopped due to Study no longer required) | ||
| A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis [NCT04218851] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-07-02 | Active, not recruiting | ||
| Modified Release Posaconazole in Patients With Cystic Fibrosis [NCT03421366] | 20 participants (Anticipated) | Observational | 2018-03-01 | Recruiting | |||
| PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE [NCT01162967] | Phase 2 | 78 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03760445] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2019-11-15 | Withdrawn(stopped due to It was determined that the study design may not be optimal given the changing AML treatment landscape.) | ||
| Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05520) [NCT01075984] | Phase 1 | 279 participants (Actual) | Interventional | 2010-02-23 | Completed | ||
| Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir [NCT00817765] | Phase 1 | 24 participants (Anticipated) | Interventional | 2009-01-31 | Completed | ||
| Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment [NCT03318159] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment [NCT02020213] | Phase 4 | 0 participants (Actual) | Interventional | 2013-12-31 | Withdrawn | ||
| Universal Posaconazole Prophylaxis Versus Pre-emptive Posaconazole Therapy for Fungal Infection Management Post-lung Transplantation [NCT03561415] | Phase 2 | 140 participants (Anticipated) | Interventional | 2018-07-02 | Not yet recruiting | ||
| A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 [NCT04665037] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-02-22 | Recruiting | ||
| Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study [NCT05065658] | 351 participants (Anticipated) | Observational | 2020-03-01 | Recruiting | |||
| Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection [NCT03717623] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection [NCT00686543] | Phase 4 | 75 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007. [NCT00704951] | 0 participants (Actual) | Observational | 2008-07-31 | Withdrawn | |||
| Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole [NCT00726609] | 214 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Single Patient Emergency Treatment Use of Posaconazole in Invasive Fungal Infections [NCT00686621] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection [NCT00811928] | Phase 3 | 252 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Investigation of POsaconazole Prophylaxis in Children With Chronic Granulomatous Disease (CGD): Pharmacokinetics and Tolerability (iPOD) [NCT00799071] | Phase 2 | 12 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary Mucormycosis [NCT05468372] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections [NCT02805946] | Phase 4 | 21 participants (Actual) | Interventional | 2017-04-28 | Completed | ||
| Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia [NCT00936117] | Phase 2 | 25 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection [NCT00811642] | Phase 3 | 63 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant [NCT00750737] | Phase 3 | 46 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [NCT01901172] | Phase 1 | 61 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections [NCT00034658] | Phase 3 | 336 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors. [NCT01951430] | 229 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrom [NCT01200355] | Phase 4 | 113 participants (Actual) | Interventional | 2010-09-09 | Completed | ||
| PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia [NCT03828773] | 320 participants (Anticipated) | Interventional | 2019-02-11 | Recruiting | |||
| Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis [NCT02875743] | Phase 4 | 120 participants (Actual) | Interventional | 2016-12-07 | Completed | ||
| Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice [NCT01436578] | 273 participants (Actual) | Observational | 2012-02-29 | Completed | |||
| An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail [NCT00491764] | Phase 2 | 218 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients [NCT02968134] | Phase 4 | 8 participants (Actual) | Interventional | 2017-01-16 | Completed | ||
| A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease [NCT04966585] | Phase 4 | 24 participants (Anticipated) | Interventional | 2022-08-17 | Recruiting | ||
| A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy [NCT02203773] | Phase 1 | 212 participants (Actual) | Interventional | 2014-10-06 | Terminated(stopped due to Strategic considerations) | ||
| Efficacy, Safety and Serum Concentration of Posaconazole Tablets for Prevention of Pulmonary Fungal Infections in Patients With Hematopoietic Stem Cell Transplantation: An Open, Prospective, Observational, Multicenter Cohort Study [NCT04725942] | 360 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095 [NCT00177749] | Phase 4 | 10 participants | Interventional | 2004-08-31 | Terminated(stopped due to Study is complete Analysis is complete) | ||
| Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections [NCT00033982] | Phase 3 | 50 participants | Interventional | 2002-04-11 | Completed | ||
| [NCT00034645] | Phase 3 | 600 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia [NCT04194086] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2018-11-01 | Completed | ||
| Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections [NCT00034632] | Phase 3 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts [NCT00034671] | Phase 2 | 98 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients [NCT00044486] | Phase 3 | 602 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial [NCT04825275] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2022-02-08 | Recruiting | ||
| Effect of Inflammation on Pharmacokinetics of Posaconazole [NCT02492802] | 64 participants (Actual) | Observational | 2015-08-13 | Completed | |||
| An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects [NCT03095547] | Phase 1 | 0 participants (Actual) | Interventional | 2017-05-31 | Withdrawn(stopped due to study no longer required in current format) | ||
| A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) [NCT01782131] | Phase 3 | 585 participants (Actual) | Interventional | 2013-09-25 | Completed | ||
| A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area [NCT02372357] | Phase 4 | 14 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients [NCT00002446] | Phase 3 | 300 participants | Interventional | 1998-08-31 | Completed | ||
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial [NCT04876716] | Phase 3 | 650 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients [NCT01667107] | Phase 4 | 26 participants (Actual) | Interventional | 2013-01-23 | Terminated(stopped due to Study terminated due to an unfavorable risk-benefit analysis) | ||
| Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections [NCT02387983] | Phase 1 | 65 participants (Actual) | Interventional | 2015-05-06 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients [NCT00002399] | Phase 2 | 500 participants | Interventional | Completed | |||
| Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp [NCT02714504] | 239 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children [NCT02358499] | Phase 1 | 31 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles [NCT03066011] | 2,015 participants (Actual) | Observational | 2017-03-16 | Completed | |||
| An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) [NCT04752163] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2021-03-25 | Completed | ||
| An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects [NCT01984229] | Phase 1 | 23 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| "A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The TIP Study." [NCT00550732] | Phase 2 | 40 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615) [NCT01777763] | Phase 1 | 230 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients [NCT03378479] | Phase 4 | 88 participants (Actual) | Interventional | 2017-12-27 | Completed | ||
| Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579) [NCT01716234] | Phase 1 | 142 participants (Actual) | Interventional | 2008-04-17 | Terminated(stopped due to Study was terminated early (10 July 2015) based on preliminary analysis of pharmacokinetic data.) | ||
| A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia [NCT02452034] | Phase 1 | 118 participants (Actual) | Interventional | 2015-09-07 | Completed | ||
| A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection [NCT02180165] | Phase 3 | 116 participants (Actual) | Interventional | 2014-07-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||